<!DOCTYPE html>
<html>
<head>
    <meta charset="utf-8" />
    <!-- Website Design By: www.happyworm.com -->
    <title>E Module</title>
    <!-- fonticon -->
    <link href="../common/css/font-awesome.css" rel="stylesheet" />
    <!-- textillate -->
    <link href="../common/css/animate.css" rel="stylesheet">
    <link href="../common/css/style.css" rel="stylesheet">
    <link href="../common/css/table.css" rel="stylesheet">
    <link href="../common/css/bluetable.css" rel="stylesheet">
    <!-- bootstrap -->
    <link rel="stylesheet" href="../common/css/bootstrap.min.css">
    <link rel="stylesheet" href="../common/css/bootstrap-theme.min.css">
    <link href="../common/css/sticky-footer.css" rel="stylesheet">
    <!-- slide bar -->
    <link href="../common/css/mbExtruder.css" media="all" rel="stylesheet" type="text/css">
    <!-- custom styles -->
    <link href="../common/css/common.css" media="all" rel="stylesheet" type="text/css">
    <!-- jquery Slider -->
    <link href="../common/css/simple-slider.css" rel="stylesheet" type="text/css" />
    <link href="../common/css/simple-slider-volume.css" rel="stylesheet" type="text/css" />
    <!-- tooltip -->
    <link href="../common/css/tipsy.css" rel="stylesheet" type="text/css" />
    <!-- image efect -->
    <link rel="stylesheet" href="../common/css/hoverEx.css" />
    <link rel="stylesheet" href="../common/css/emodule.image.css" />
    <!-- jquery dropdown -->
    <link type="text/css" rel="stylesheet" href="../common/css/jquery.dropdown.css" />
    <!-- scripts-->
    <!-- Latest compiled and minified JavaScript -->

    <script type="text/javascript" src="../common/js/jquery-1.9.1.js"></script>

    <script type="text/javascript" src="../common/js/jquery-ui.js"></script>

    <script type="text/javascript" src="../common/js/jquery.dropdown.js"></script>

    <!-- simple slider -->

    <script src="../common/js/simple-slider.js"></script>

    <!-- bootstrap -->

    <script src="../common/js/bootstrap.min.js"></script>

    <!-- slide bar -->

    <script type="text/javascript" src="../common/js/jquery.hoverIntent.min.js"></script>

    <script type="text/javascript" src="../common/js/jquery.mb.flipText.js"></script>

    <script type="text/javascript" src="../common/js/mbExtruder.js"></script>

    <!-- textillate -->

    <script src="../common/js/jquery.fittext.js"></script>

    <script src="../common/js/jquery.lettering.js"></script>

    <script src="../common/js/jquery.textillate.js"></script>

    <!-- tooltip -->

    <script src="../common/js/jquery.tipsy.js"></script>

    <script src="../common/js/jquery.zoom.js"></script>

    <script type="text/javascript">
        $(function () {
            $("#extruderLeft2").buildMbExtruder({
                position: "left",
                width: 200,
                positionFixed: false,
                top: 125,
                extruderOpacity: .8,
                onExtOpen: function () { },
                onExtContentLoad: function () { },
                onExtClose: function () { }
            });
        });

        function PlayEvents() {
        }
        PlayEvents.prototype.onAudioFailed = function () {
            alert("Failed to load audio.");
        }

        var coursePlayer = null;

        function onLoadSlidebyID(ID) {
            coursePlayer.LoadbySlide(ID);
        }

        function Init() {
            document.getElementById('slideLabel').style.display = 'block';
            coursePlayer = new CoursePlayer("moduleAudio", new PlayEvents());
            coursePlayer.initialize("emodule7.xml");
            coursePlayer.play();
        }

        function Next() {
            if (coursePlayer.nextSlide())
                coursePlayer.play();
        }
        function Prev() {
            if (coursePlayer.prevSlide())
                coursePlayer.play();
        }

        function play() {
            if (!coursePlayer.getPlayerStatus()) {
                document.getElementById("toggelbutton").src = "../common/img/pauseBtn.png";
                coursePlayer.play();
            }
            else {

                document.getElementById("toggelbutton").src = "../common/img/playBtn.png";
                coursePlayer.pause();
            }
        }


        //]]>
    </script>

    <!-- course player -->

    <script src="../common/js/player/CoursePlayer.js"></script>

    <script src="../common/js/player/TrackerService.js"></script>

    <script src="../common/js/custom.js"></script>

</head>
<body style="overflow-x: hidden; font-family: Verdana" onload="createAttempt();">
    <div id="wrap" style="width: 1024px;">
        <div class="" style="height: 90px;">
            <div class="header-top">
            </div>
            <div class="header-body">
                <img src="../common/img/logo.png" class="logo" />
                <div class="header-help">
                    <h3 id="slideTitle" class="module-title"></h3>
                    <div style="float: right">
                        <img class="effect" onmouseover="HideToolTip(this)" onclick="onclickPlaylistImg()"
                            data-toggle="tooltip" data-placement="left" title="Playlist" style="float: left; opacity: 0.7; width: 36px; margin-top: 14px; margin-right: 8px;"
                            src="../common/img/content.png" />
                        <img class="effect" onmouseover="HideToolTip(this)" data-horizontal-offset="-10"
                            data-dropdown="#dropdown-6" data-toggle="tooltip" data-placement="bottom" title="Reference"
                            style="float: left;" src="../common/img/smallicon1.png" />
                        <img class="effect" onclick="onclickGlossaryImg()" onmouseover="HideToolTip(this)"
                            data-toggle="tooltip" data-placement="customTooltip" title="Glossary" style="float: left; margin-right: 40px;"
                            src="../common/img/smallicon4.png" />
                        <img class="headerleftbg" src="../common/img/headerCorBg.png" />
                    </div>
                </div>
                <div id="dropdown-6" class="dropdown dropdown-tip dropdown-anchor-right has-icons">
                    <div class="dropdown-panel">
                    </div>
                </div>
            </div>
            <audio id="moduleAudio"></audio>
        </div>
        <div style="position: relative; height: 615px;">
            <!--<div id="extruderLeft2" class="a {title:'Slides\'s', url:'parts/extruderLeft.html'}">
                <div class="playlist" style="height: 615px;">
                    <div class="playlist-header"></div>
                    <div id="playlist" class="playlist-item">
                        <div class="list-items">title <span>0:00</span></div>
                    </div>
                    <div class="playlist-footer">
                        <p>Total Duration : <span id="totalDuration">00:00</span></p>
                    </div>
                </div>

            </div>-->
            <div class="slidePlayer">
                <div id="PlayListDiv" style="display: none;">
                    <div class="coursecontent" style="height: 600px; width: 100%;">
                        <div class="playlist-header">
                            <button type="button" class="header-close" onclick="onclickClosePlaylist()" style="float: right;">
                                close</button>
                        </div>
                        <div id="playlist" class="playlist-item  style-5">
                            <div class="list-items">
                                title <span>0:00</span>
                            </div>
                        </div>
                        <div class="playlist-footer">
                            <p>
                                Total Duration : <span id="totalDuration">00:00</span>
                            </p>
                        </div>
                    </div>
                </div>
                <div id="GlossaryDiv" style="display: none;">
                    <div class="coursecontent" style="height: 600px; width: 100%;">
                        <div class="playlist-header">
                            <button type="button" class="header-close" onclick="onclickCloseglossary()" style="float: right;">
                                Close</button>
                        </div>
                        <div id="Div2" class="playlist-item  style-5">
                            <div id="GlossaryTitle" class="GlossaryTitle style-5">
                            </div>
                            <div id="GlossaryData" class="GlossaryData style-5">
                            </div>
                        </div>
                        <div class="playlist-footer">
                        </div>
                    </div>
                </div>



                <div id="slide0" style="display: none;">


                    <div class="slidecontent" style="">
                        <div class="playBody">

                            <div data-class="fadeInDown" class="breakout" style="display: none; margin-left: 30px; margin-top: 230px; text-align: center;"
                                id="S0P1">
                                <p style="padding-left: 40px; font-size: 20px;">
                                    ADCETRIS Objection Handler module
                                </p>
                            </div>

                        </div>





                    </div>




                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none; position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center> <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);" > Hide Transcript</button></center>
                        <div class="transcript" style="">
                            <p>
                                Welcome to ADCETRIS Objection Handler module. 
                            </p>





                        </div>
                    </div>
                </div>







                <div id="slide1a" style="display: none;">
                    <div id="slide1aref" style="display: none;" class="slide1aref">
                        <b>No References:</b><br />
                    </div>


                    <div class="slidecontent" style="">
                        <div class="playBody">

                            <p id="S1bP1" style="display: none; padding-left: 20px; padding-top: 16px;"><b>Steps of objection handling:</b></p>

                            <div id="bimg1a" style="display: none; padding-left: 40px; padding-top: 5px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="padding-top: 0px">Listen and acknowledge</p>
                            </div>
                            <div id="bimg2a" style="display: none; padding-left: 60px; padding-top: 0px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">Make it clear to your customer that you have heard the objection</p>
                            </div>
                            <div id="bimg3a" style="display: none; padding-left: 60px; padding-top: 0px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">Show that you recognize and will address their concern, without agreeing with it</p>
                            </div>
                            <div id="bimg4a" style="display: none; padding-left: 40px; padding-top: 0px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">Clarify and understand</p>
                            </div>
                            <div id="bimg5a" style="display: none; padding-left: 60px; padding-top: 0px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">Break down the objection and find out more about the beliefs behind it</p>
                            </div>
                            <div id="bimg6a" style="display: none; padding-left: 60px; padding-top: 0px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px; margin-bottom: 45px;" />
                                <p data-class="fadeInDown" style="">Clarifying will help you to determine whether the objection arises from a misunderstanding, a need for more information, apathy, or a bad impression</p>
                            </div>
                            <div id="bimg7a" style="display: none; padding-left: 40px; padding-top: 0px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">Handle and inform</p>
                            </div>
                            <div id="bimg8a" style="display: none; padding-left: 60px; padding-top: 0px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">Respond to the extent of the objection</p>
                            </div>
                            <div id="bimg9a" style="display: none; padding-left: 60px; padding-top: 0px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">Present clear information to address the reason or reasons behind the concern</p>
                            </div>
                            <div id="bimg10a" style="display: none; padding-left: 40px; padding-top: 0px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">Expand and close</p>
                            </div>
                            <div id="bimg11a" style="display: none; padding-left: 60px; padding-top: 0px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">Provide any additional information that covers the query and is in-label that your customer is interested in</p>
                            </div>
                            <div id="bimg12a" style="display: none; padding-left: 60px; padding-top: 0px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">Move on from the objection and continue the sales call</p>
                            </div>




                        </div>
                    </div>



                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none; position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center> <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);" > Hide Transcript</button></center>
                        <div class="transcript" style="">
                            <p>
                                The process of handling objections involves 4 steps which require you to listen and acknowledge, clarify and understand, handle and inform and finally expand and close the discussion.

                            </p>
                            <p>
                                The first step of the process is to ‘Listen and acknowledge’. Your initial response should make it clear to your customer that you have heard the objection. The aim here is to show that you recognise and will address their concern, without agreeing with it.
                            </p>
                            <p>
                                You should then ‘Clarify and understand’. Ask questions to break down the objection and find out more about the beliefs behind it. This will enable you to understand and address the concern effectively. Clarifying will help you to determine whether the objection arises from a misunderstanding, a need for more information, apathy, or a bad impression.

                            </p>
                            <p>After you understand the concern you should ‘handle and inform’ them. This is where you respond to the extent of the objection and present clear information to address the reason or reasons behind the concern.</p>
                            <p>
                                Once you have addressed the concern you can expand with more pertinent information and later close the discussion. You can provide any additional information that covers the query and is in-label that your customer is interested in. You will now need to move on from the objection and continue the sales call.
                            </p>


                        </div>
                    </div>
                </div>


                <div id="slide1b" style="display: none;">

                    <div id="slide1bref" style="display: none;" class="slide1bref">
                        <b>No References:</b><br />
                        
                    </div>


                    <div class="slidecontent" style="">
                        <div class="playBody">
                            <div id="bimg1" style="display: none; padding-left: 40px; padding-top: 29px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 36px; margin-bottom: 75px;" />
                                <p data-class="fadeInDown" style="padding-top: 30px">This module is a part of an e-learning program which focuses on the different aspects of ADCETRIS, pivotal clinical trials with ADCETRIS, the role and approval for use in certain patient populations which include patients with relapsed or refractory Hodgkins lymphoma and patients with relapsed or refractory systemic anaplastic large-cell lymphoma.</p>
                            </div>
                            <div id="bimg1a" style="display: none; padding-left: 40px; padding-top: 29px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px; margin-bottom: 70px;" />
                                <p data-class="fadeInDown" style="">The material presented as part of this e-learning program is strictly for internal training purposes only. It shall neither be shared or used outside of Takeda nor being used as a tool to prepare and provide (non-) promotional material. </p>
                            </div>
                            <div id="bimg1b" style="display: none; padding-left: 40px; padding-top: 29px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">The content is based on the state of knowledge as of July 2015 </p>
                            </div>
                            <div id="bimg2" style="display: none; padding-left: 40px; padding-top: 29px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px; margin-bottom: 70px;" />
                                <p data-class="fadeInDown" style="">This module is aligned with the content in the Objection handler. The Objection Handler demonstrates the 4-step process to conduct a good dialogue while handling objections posed by the customer. This training will provide the supporting marketing resources  and approved messages. </p>
                            </div>


                           <!-- <div id="bimg1" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">This module is a part of an e-learning program which focuses on the different aspects of ADCETRIS, pivotal clinical trials with ADCETRIS, the role and approval for use in certain patient populations which include patients with relapsed or refractory Hodgkins lymphoma and patients with relapsed or refractory systemic anaplastic large-cell lymphoma.</p>
                            </div>
                            <div id="bimg1a" style="display: none; padding-left: 69px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">The material presented as part of this e-learning program is strictly for internal training purposes only. It shall neither be shared or used outside of Takeda nor being used as a tool to prepare and provide (non-) promotional material.</p>
                            </div>
                            <div id="bimg1b" style="display: none; padding-left: 69px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">The content is based on the state of knowledge as of July 2015</p>
                            </div>
                            <div id="bimg2" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">This module is aligned with the content in the Objection handler. The Objection Handler demonstrates the 4-step process to conduct a good dialogue while handling objections posed by the customer. This training will provide the supporting marketing resources  and approved messages.</p>
                            </div>
                            <div id="bimg2a" style="display: none; padding-left: 69px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">Break down the objection and find out more about the beliefs behind it</p>
                            </div>
                            <div id="bimg2b" style="display: none; padding-left: 69px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px; margin-bottom: 29px;" />
                                <p data-class="fadeInDown" style="">Clarifying will help you to determine whether the objection arises from a misunderstanding, a need for more information, apathy, or a bad impression</p>
                            </div>
                            <div id="bimg3" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">Handle and inform</p>

                            </div>
                            <div id="bimg3a" style="display: none; padding-left: 69px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">Respond to the extent of the objection</p>

                            </div>
                            <div id="bimg3b" style="display: none; padding-left: 69px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">Present clear information to address the reason or reasons behind the concern</p>

                            </div>
                            <div id="bimg4" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">Expand and close</p>

                            </div>
                            <div id="bimg4a" style="display: none; padding-left: 69px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">Provide any additional information that covers the query and is in-label that your customer is interested in</p>

                            </div>
                            <div id="bimg4b" style="display: none; padding-left: 69px;">
                                <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="">Move on from the objection and continue the sales call</p>
                                <br />
                            </div>-->


                        </div>
                    </div>



                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none; position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center> <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);" > Hide Transcript</button></center>
                        <div class="transcript" style="">
                            <p>
                                This module is a part of an e-learning program which focuses on the different aspects of ADCETRIS, pivotal clinical trials with ADCETRIS, the role and approval for use in certain patient populations which include patients with relapsed or refractory Hodgkins lymphoma and patients with relapsed or refractory systemic anaplastic large-cell lymphoma. 

                            </p>
                            <p>
                                The material presented as part of this e-learning program is strictly for internal training purposes only. It shall neither be shared or used outside of Takeda nor being used as a tool to prepare and provide (non-) promotional material.
                            </p>
                            <p>
                                The content is based on the state of knowledge as of July 2015

                            </p>
                            <p>This module is aligned with the content in the Objection handler. The Objection Handler demonstrates the 4-step process to conduct a good dialogue while handling objections posed by the customer. This training will provide the supporting marketing resources  and approved messages.
                           </p>




                        </div>
                    </div>
                </div>

                <div id="Obj1a" style="display: none;">

                    <div id="Obj1aref" style="display: none;" class="Obj1aref">
                        <b>No References:</b><br />
                    </div>


                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2); overflow-y: auto;">
                        <div class="playBody">


                            <div style="height: 50%;">
                                <div data-class="fadeInDown" class="breakout" style="display: none; margin-left: 30px; margin-top: 6px; text-align: center;"
                                    id="s1atxt1">
                                    <p style="padding-left: 40px; font-size: 20px;">
                                        To begin, click on an objection you would like to explore
                                    </p>
                                </div>
                                <center>
                        <table class="leftbluetable" id="s4Table1" style=" display: none; border:1px solid #ccc; width:890px;">
                            <tr style="border-bottom: 1px solid #ccc;background-color:#d1e5f9;">
                                <td style=" width: 13%;text-align: left; color:Black; display:none;">
                                 

                                </td>
                                <td style="background-color:#d1e5f9; display:none;">
                                 
 
                                </td>
                            </tr>
							<tr style="border-bottom: 1px solid #ccc; border-top:2px solid black;">
                                <td  style="width: 13%; text-align: left; color:Black; cursor: pointer;" onclick="Next();" ;>
                               <b>Objection 01</b>

                                </td>
                                <td style=" cursor: pointer;" onclick="Next();">
                                   “I don’t see why we should continue to treat a patient when they have achieved CR early in the course of treatment”

                                </td>
                            </tr>
							
							
                            <tr style="border-bottom: 1px solid #ccc; border-top:2px solid black;">
                                <td style="width: 13%; text-align: left; color:Black; cursor: pointer;" onclick="onLoadSlidebyID(5);";>
                                   <b>Objection 02</b>

                                </td>
                                <td style="cursor: pointer;" onclick="onLoadSlidebyID(5);">
                                  “This dosing isn’t really clear; how many cycles are needed to get a response? The ADCETRIS label states that patients who achieve stable disease or better, should continue for a maximum of 16 cycles. If my patient doesn’t respond can I give them more than 16 cycles?”

                                </td>
                            </tr>
                            <tr style="border-bottom: 1px solid #ccc;">
                                <td class="" style="width: 13%; text-align: left; cursor: pointer;" onclick="onLoadSlidebyID(6);";>
                                  <b> Objection 03</b> </td>
                                <td style="cursor: pointer;" onclick="onLoadSlidebyID(6); ">
                                   “What are the main criteria for continuing ADCETRIS treatment in the 8-16 dosage cycles stated in the licence? Is there any evidence that continuation of ADCETRIS will lead to a better response?”

                                </td>
                            </tr>
                            <tr style="border-bottom: 1px solid #ccc;">
                                <td class="" style="width: 13%; text-align:justify; cursor: pointer;" onclick="onLoadSlidebyID(7);">
                                   <b>Objection 04</b>

                                </td>
                               
                                <td style=" cursor: pointer;" onclick="onLoadSlidebyID(7);">
                                    
                               “European treatment guidelines for Hodgkin lymphoma indicate several multi-agent regimens followed by ASCT, gemcitabine-based chemotherapy, novel single agents and/or regional radiotherapy: ADCETRIS is not included.”

                                   
                                </td>
                            </tr>
                            <tr style="border-bottom: 1px solid #ccc;">
                                <td class="" style=" width: 13%;text-align: left;  cursor: pointer;" onclick="onLoadSlidebyID(8);">
                                <b>Objection 05</b>

                                </td>
                                <td style="cursor: pointer;" onclick="onLoadSlidebyID(8); ">
                                 “There appears to be a clear benefit from achieving CR in terms of duration of benefit in Hodgkin lymphoma patients. However, patients with PR had only a short duration of response: is there value in treating these patients using my budget?”

                                </td>
                            </tr>
                            <tr>
                                <td class="" style="width: 13%; text-align: left; cursor: pointer;" onclick="onLoadSlidebyID(9);">
                                 <b>Objection 06</b>    </td>
                                <td style="cursor: pointer;" onclick="onLoadSlidebyID(9);">
                                 “Can we expect to see the same response rates in real life or was the data/patient selection biased?”

                                </td>
                            </tr>
                            <tr style="border-bottom: 1px solid #ccc;">
                                <td class="" style="width: 13%; text-align: left; cursor: pointer;" onclick="onLoadSlidebyID(10);">
                                  <b>Objection 07</b>

                                </td>
                               
                                <td style=" cursor: pointer;" onclick="onLoadSlidebyID(10);">
                              “The data for transplant-ineligible patients are inconclusive. Why should I trust the data?”

                                </td>
                            </tr>
                            <tr style="border-bottom: 1px solid #ccc;">
                                <td style="width: 13%;text-align: left; cursor: pointer;" onclick="onLoadSlidebyID(11);">
                                 <b> Objection 08</b>

                                </td>
                                <td style="cursor: pointer;" onclick="onLoadSlidebyID(11); ">
                                “The sALCL patient group is very small.”

                                </td>
                            </tr>
                            <tr style="border-bottom: 1px solid #ccc;">
                                <td class="" style=" width: 13%;text-align: left;  cursor: pointer;" onclick="onLoadSlidebyID(12);">
                               <b>Objection 09</b>

                                </td>
                               
                                <td style=" cursor: pointer;" onclick="onLoadSlidebyID(12); ">
                                “There appears to be clear benefit from achieving CR in terms of duration of response in sALCL patients. However, patients wita h PR had a shorter duration of response, so is there value in treating these patients?”

                                </td>
                            </tr>
                            <tr style="border-bottom: 1px solid #ccc;">
                                <td style="width: 13%; text-align: left; cursor: pointer;" onclick="onLoadSlidebyID(13);">
                                    <b>Objection 10</b>


                                </td>
                                <td style=" cursor: pointer;" onclick="onLoadSlidebyID(13);">
                                “I am concerned that there are limited data on survival with ADCETRIS in relapsed or refractory sALCL patients”
 

                                </td>
                            </tr>
                            <tr style="border-bottom: 1px solid #ccc;">
                                <td style="width: 13%;text-align: left; cursor: pointer;" onclick="onLoadSlidebyID(14);">
                                  <b>Objection 11</b>

                                </td>
                               
                                <td style="cursor: pointer;" onclick="onLoadSlidebyID(14);">
                                “Why should I prescribe ADCETRIS to my pre-SCT patients when I achieve good response rates with the cheaper bendamustine?”

                                </td>
                            </tr>
                            <tr style="border-bottom: 2px solid black;">
                                <td  style="width: 13%; text-align: left; cursor: pointer;" onclick="onLoadSlidebyID(15);">
                                 <b>Objection 12</b>

                                </td>
                               
                                <td style=" cursor: pointer;" onclick="onLoadSlidebyID(15);">
                                  “I have good experiences prescribing gemcitabine-based regimens to relapsed/refractory Hodgkin lymphoma and sALCL patients; therefore, I see no reason why I should try ADCETRIS?”

                                </td>
                            </tr>
                        </table>
                        </center>




                            </div>
                        </div>

                    </div>




                </div>


                <div id="Obj1" style="display: none;">

                    <div id="Obj1ref" style="display: none;" class="Obj1ref">
                        <!--<b>No References:</b><br />-->
                     
                    </div>



                    <!-- <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div class="playBody">
                            <div data-class="fadeInDown" class="breakout" style="display: none; margin-left: 30px; margin-top: 250px; text-align: center;"
                                id="s0txt1">
                                <p style="padding-left: 40px; font-size: 20px;">
                                    Objection 1
                                    <br />
                                    Dosing and Duration of Treatment

                                </p>
                            </div>
                        </div>
                    </div>-->

                </div>


                <div id="slide1" style="display: none;" class="slide1ref">

                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">




                        <div id="slide1ref" style="display: none;" class="slide1ref">
                            <!--<b>No  References</b><br />-->
                            <ol>
                                <li>
                                    Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, et al,. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.<i> J Clin Oncol.</i> 2012 Jun 20;30(18):2183-9.
                                </li>
<li>
    Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.<i> J Clin Oncol.</i>  2012;30(18):2190-6.

</li>
                                <li>
                                    Gopal AK, et al. Poster abstract no. 4382 presented at American Society of Hematology, December 2013, New Orleans, LA, USA.
                                </li>
                                <li>
                                    Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD et al. Three-year survival results from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Poster, Abstract No. 1809, American Society of Hematology, December, 2013, New Orleans, LA, USA.

                                </li>
                                <li>
                                    ADCETRIS®. Summary of Product Characteristics. 22 August 2014. Available at European Medicines Agency Web site http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002455/WC500135055.pdf. Accessed on 26 June 2015.

                                </li>
                                <li>
                                    Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD et al. Four-year survival results from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Poster, Abstract No. 3095, American Society of Hematology, December, 2014, San Francisco, CA, USA.

                                </li>
                            </ol>
                        </div>
                        <div class="playBody" style="margin-top: 10px; overflow: hidden;">
                            <div data-class="fadeInDown" class="breakout" style="display: none; margin-left: 30px;text-align: center;"
                                id="s0txt1">
                                <p style="padding-left: 40px; font-size: 20px;">
                                    Objection 1
                                    <br />
                                    “I don’t see why we should continue to treat a patient when they have achieved CR early in the course of treatment”


                                </p>
                            </div>
                            <div>
                                <img src="img/S0BG1.png" data-class="fadeIn" id="slide0img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />
                                <img src="img/S0txt1.png" data-class="fadeIn" id="slide0img2" style="display: none; width: 243px; float: right; margin-right: 357px; position: relative; margin-top: 10px;" />
                            </div>
                            <div>
                                <img src="img/S1BG1.png" data-class="fadeIn" id="slide1img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />
                                <img src="img/S1txt1.png" data-class="fadeIn" id="slide1img2" style="display: none; width: 243px; float: right; margin-right: 332px; position: relative; margin-top: 10px;" />
                            </div>
                            <div>
                                <div>
                                    <img src="img/S2BG2.png" data-class="fadeIn" id="slide2img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px; height: 514px;" />
                                </div>
                                <p id="txt1" style="margin-left: 140px; padding-top: 78px; color: #FFF; display: none; position: relative;">
                                    Here are some questions you may ask:
                                </p>
                                <ul style="margin-left: 60px; padding-top: 20px; width: 580px;">
                                    <div data-class="fadeIn" id="txt2" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">What are the important factors that lead you to decide to
                                        take early responders off treatment; are your concerns related to tolerability,
                                        cost/time/resources, treatment goals achieved/allogenic stem cell transplant?</li>
                                        <br />
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="txt3" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">How important is duration of response in your treatment goals?
                                        </li>
                                        <br />
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="txt4" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">What are your expectations of duration of response for your
                                        early responders?</li>
                                    </div>
                                </ul>
                            </div>
                            <div>
                                <img src="img/S3txt1.png" data-class="fadeIn" id="slide3img1" style="display: none; width: 230px; margin-left: 381px; margin-top: -20px; position: relative;" />
                            </div>
                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="slide4img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none;" />
                                <div class="text" style="margin-left: 38px;">


                                    <div data-class="fadeIn" id="s4txt1" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            The medical history of these patients shows that they have relapsed after achieving a CR/PR, or have never achieved a CR/PR before.<sup>2</sup>
                                        </p>
                                        <br />

                                    </div>
                                    <!--<div data-class="fadeIn" id="s4txt2" style="display: none;margin-top: -14px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            If treatment is stopped as soon as complete response with ADCETRIS is observed, there is a risk that the response will be lost.
                                        </p>

                                    </div>-->
                                    <div data-class="fadeIn" id="s4txt3" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            Therefore, once CR is achieved, patients should be treated in accordance with the ADCETRIS label, and continue the treatment regimen until disease progression or unacceptable toxicity. Up to 16 cycles or approximately 1 year and no less than 8 cycles of ADCETRIS is recommended even if stable disease is achieved.<sup>5</sup>                                        </p>
                                        <br />
                                    </div>
                                </div>

                            </div>
                            <div style="width: 45%; float: right; margin-top: -21px; margin-right: -30px;">
                                <img src="img/S6P1.png" data-class="fadeIn" id="slide4img2a" style="width: 200px; display: none; margin-bottom: 9px; margin-top: 25px;" />
                                <img src="img/S4P1.png" data-class="fadeIn" id="slide4img2" style="width: 200px; display: none; margin-bottom: 44px; margin-top: 25px;" />
                                <img src="img/S4G1.png" data-class="fadeIn" id="slide4img3" style="display: none;" />
                            </div>
                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="slide5img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none;" />
                                <div class="text" style="margin-left: 38px;">
                                    <br />
                                    <div data-class="fadeIn" id="s5txt1" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            In the pivotal Hodgkin lymphoma study, patients received a median of 9 cycles (range,
                                            1 to 16) and in the pivotal sALCL study, patients received a median of 7 cycles
                                            (range, 1 to 16).<sup>1,2</sup>
                                        </p>
                                    </div>
                                     
                                </div>

                            </div>
                            <div style="width: 45%; float: right; margin-top: -21px; margin-right: -30px;">
                                <img src="img/S6P1.png" data-class="fadeIn" id="slide5img2a" style="width: 200px; display: none; margin-bottom: 22px; margin-top: 25px;" />
                                <img src="img/O1G2.png" data-class="fadeIn" id="slide5img4" style="display: none; margin-bottom: -22px; margin-top: 35px;height: 80px;" />
                            </div>

                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="slide0img1a" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none;" />
                                <div class="text" style="margin-left: 38px;">
                                    <div data-class="fadeIn" id="s5txt3" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            The ADCETRIS label states that patients who achieve stable disease or better should receive a minimum of 8 cycles and up to a maximum of 16 cycles (approximately 1 year). Treatment should be continued until disease progression or unacceptable toxicity.<sup>5</sup>
                                        </p>
                                        <br />
                                    </div>
                                </div>
                            </div>

                            <br />



                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">

                                <img id="slide0img0" alt="" src="img/S4BG1.png" style="width: 400px; height: 183px; margin-left: 62px; margin-top: -8px; display: none;" />
                                <div class="text" style="margin-left: 38px;">
                                    <div data-class="fadeIn" id="s5txt2" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            In both trials patients who achieved an objective response (CR, or PR) received more cycles of therapy.<sup>3,4</sup>
                                        </p>
                                        <br />
                                    </div>
                                </div>
                                <div style="width: 45%; margin-top: -21px; margin-right: -30px;">
                                    <img src="img/pdf8img1a.png" data-class="fadeIn" id="slide5img3a" style="display: none; margin-bottom: -22px; margin-top: 49px; margin-left: 83px;" />
                                </div>
                            </div>
                            <div style="width: 45%; float: left;">
                            </div>
                            <div style="width: 45%; float: right; margin-top: -21px; margin-right: -30px;">
                                <!--  <img src="img/S6P1.png" data-class="fadeIn" id="slide5img2a" style="width: 200px; display: none; margin-bottom: 22px; margin-top: 25px;" />
                              -->
                                <img src="img/S4P1.png" data-class="fadeIn" id="slide5img2" style="width: 200px; display: none; margin-bottom: 9px; margin-top: -723px;" />
                                <img src="img/pdf8img2a.png" data-class="fadeIn" id="slide5img3" style="display: none; margin-top: 25px;" />
                                <img src="img/S4G1.png" data-class="fadeIn" id="slide5img5" style="display: none; margin-top: -265px;" />
                            </div>
                            <div>
                                <div>
                                    <img src="img/S1BG1.png" data-class="fadeIn" id="slide6img1" style="display: none; position: absolute; width: 75%; margin-left: 99px; margin-top: -40px;" />
                                    <img src="img/S2BG2.png" data-class="fadeIn" id="slide6img2" style="display: none; position: absolute; width: 75%; margin-left: 99px; height: 519px; margin-top: -42px;" />
                                    <div style="color: white; margin-left: 95px; position: relative;">
                                        <p id="s6txt1" style="color: white; padding-top: 130px; padding-left: 62px; width: 748px; display: none;">
                                          <b>  Check to establish customer acceptance of this response, and identify any outstanding
                                        aspects of this objection to address.</b>
                                        </p>
                                        <br />
                                        <br />
                                        <p id="s6txt2" style="color: white; padding-left: 62px; width: 748px; display: none;">
                                            Emphasise the benefits of continuing ADCETRIS when following the licensed indication.
                                        </p>
                                    </div>
                                </div>
                            </div>

                            <div class="image" style="width: 44%; float: left; margin-right: 100px; margin-top: -61px;">
                                <img id="slide7img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none; height: 200px;" />
                                <div class="text" style="margin-left: 25px;">
                                    <div data-class="fadeIn" id="s7txt1" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            ADCETRIS is a treatment option for patients who can achieve a long duration of survival. However, patients must be treated according to the license to give patients the best possibility of achieving optimal outcomes.

                                        </p>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="s7txt2" style="display: none; margin-top: 5px; width: 386px; margin-left: -10px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            Moreover, when used for the licensed period, Hodgkin lymphoma patients had a median OS of 40.5 months and sALCL patients had a median OS of 55.1 months.<sup>3,6</sup>

                                    </div>
                                </div>
                                <div>
                                    <img src="img/HL.png" data-class="fadeIn" id="heading1" style="display: none; margin-bottom: -11px; margin-left: 223px; margin-top: 14px;" />
                                    <img src="img/pdf9img1a.png" data-class="fadeIn" id="slide7img3a" style="display: none; margin-bottom: 9px; margin-top: 17px; margin-left: 93px;" />
                                </div>
                            </div>

                            <div style="width: 45%; float: right; margin-top: -80px; margin-right: -30px;">


                                <img src="img/S4P1.png" data-class="fadeIn" id="slide7img2" style="width: 180px; display: none; margin-bottom: 71px; margin-top: 26px;" />


                                <img src="img/sALCL.png" data-class="fadeIn" id="heading2" style="display: none; margin-top: 228px; margin-left: -47px;" />
                                <img src="img/pdf9img2a.png" data-class="fadeIn" id="slide7img3" style="display: none;margin-top: -3px;" />

                            </div>

                        </div>
                    </div>
                </div>
                <div id="Obj2" style="display: none;">

                    <div id="Obj2ref" style="display: none;" class="Obj2ref">
                        <b>No References</b><br />
                    </div>



                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div class="playBody">
                        </div>
                    </div>

                </div>
                <div id="slide2" style="display: none;" class="slide1ref">
                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div id="slide2ref" style="display: none;" class="slide2ref">
                            <!--<b>No References</b><br />-->
                            <ol>
                                <li>
                                    ADCETRIS®. Summary of Product Characteristics. 22 August 2014. Available at European Medicines Agency Web site http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002455/WC500135055.pdf. Accessed on 26 June 2015.

                                </li>
                                <li>
                                    Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, et al,. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. i>J Clin Oncol</i>. 2012 Jun 20;30(18):2183-9.

                                </li>
                                <li>
                                    Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. <i>J Clin Oncol</i>. 2012;30(18):2190-6.

                                </li>
                            </ol>
                        </div>
                        <div class="playBody" style="margin-top: 10px; overflow: hidden;">
                            <div data-class="fadeInDown" class="breakout" style="display: none; margin-left: 30px; text-align: center;"
                                id="S2txt1">
                                <p style="padding-left: 40px; font-size: 20px;">
                                    Objection 2
                                    <br />
                                    “This dosing isn’t really clear; how many cycles are needed to get a response? The ADCETRIS label states that patients who achieve stable disease or better, should continue for a maximum of 16 cycles. If my patient doesn’t respond can I give them more than 16 cycles?”


                                </p>
                            </div>
                            <div>
                                <img src="img/S0BG1.png" data-class="fadeIn" id="o2image" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />

                                <img src="img/O2txt.png" data-class="fadeIn" id="o2text" style="display: none; width: 215px; float: right; margin-right: 358px; position: relative; margin-top: 10px;" />
                            </div>
                            <div>
                                <img src="img/S1BG1.png" data-class="fadeIn" id="s2img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />
                                <img src="img/O2txt1.png" data-class="fadeIn" id="s2txt1" style="display: none; width: 220px; float: right; margin-right: 358px; position: relative; margin-top: 10px;" />
                            </div>
                            <div>
                                <div>
                                    <img src="img/S2BG2.png" data-class="fadeIn" id="s2img2" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px; height: 514px;" />
                                </div>
                                <p id="o2txt1" style="margin-left: 140px; padding-top: 78px; color: #FFF; display: none; position: relative; width: 688px;">
                                    You can get a better understanding of the customer’s inquiry by trying to gain insight
                                into their particular concern. The following are a few questions you may ask
                                </p>
                                <ul style="margin-left: 34px; padding-top: 20px; width: 772px;">
                                    <div data-class="fadeIn" id="o2txt2" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">How does the licensed dosage of 8-16 cycles fit in with your
                                        expectations and treatment pathway?</li>
                                        <br />
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o2txt3" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">What concerns do you have about keeping patients on the treatment
                                        for between 8 and 16 cycles? </li>
                                        <br />
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o2txt4" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">Would you like to look at data exploring why the licensed
                                        treatment period is 8-16 cycles?</li>
                                    </div>
                                </ul>
                            </div>
                            <div>
                                <img src="img/O2txt2.png" data-class="fadeIn" id="s2txt2" style="display: none; width: 217px; float: right; margin-right: 357px; position: relative; margin-top: -23px;" />
                            </div>
                            <div>
                                <img src="img/O2txt3.png" data-class="fadeIn" id="s2txt3" style="display: none; width: 217px; float: right; margin-right: 357px; position: relative; margin-top: -23px;" />
                            </div>
                            <div class="image" style="width: 44%; float: left; margin-right: 116px;">
                                <img id="o2slide4img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none" />
                                <div class="text" style="margin-left: 28px; margin-top: -19px; width: 368px; font-size: 3pt;">

                                    <div data-class="fadeIn" id="o2s4txt1" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            In the trial with patients with Hodgkin lymphoma the time to individual response
                                    ranged from 5.1 to 56 weeks. Although the majority of responses did occur early
                                    in the course of treatment, at least one instance of complete remission (CR) was
                                    initially documented approximately 1 year after initiation of therapy.<sup>2</sup>
                                        </p>
                                        <br />

                                    </div>
                                    <div data-class="fadeIn" id="o2s4txt2" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            Similarly, in the pivotal sALCL study, the median time to OR was 5.9 weeks and the
                                    time to individual responses ranged from 4.3 to 14 weeks. Also, the last instance
                                    of CR in this study was observed almost 1 year after initiation of therapy.<sup>3</sup>
                                        </p>
                                        <br />

                                    </div>

                                    <div class="image" style="width: 44%; float: left; margin-right: 100px;">

                                        <img id="S2image2" alt="" src="img/S4BG1.png" style="width: 401px; height: 183px; margin-left: -18px; margin-top: 2px; display: none;" />
                                        <div class="text" style="margin-left: 41px; margin-top: -19px; width: 368px; font-size: 3pt;">

                                            <div data-class="fadeIn" id="o2s4txt3" style="display: none; margin-left: -122px; width: 385px;">
                                                <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                                <p style="padding-left: 30px; text-align: left;">
                                                    Patients received a median of 7 cycles in the Hodgkin lymphoma trial and a median
                                    of 9 cycles in the sALCL study.<sup>1,2</sup> In both trials patients who achieved an objective
                                    response (CR or PR) received more cycles of therapy.<sup>2,3</sup>
                                                </p>
                                                <br />
                                            </div>
                                            <div data-class="fadeIn" id="o2s5txt1" style="display: none; margin-left: -122px; width: 385px;">
                                                <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                                <p style="padding-left: 30px; text-align: left;">
                                                    In summary, responses were seen in the pivotal trials following up to 1 year of
                                    therapy, highlighting the importance of continuing treatment up to <b>16 cycles which
                                    is approximately equivalent to 1 year of treatment.</b>
                                                </p>
                                                <br />

                                            </div>
                                            <div data-class="fadeIn" id="o2s5txt2" style="display: none; margin-left: -122px; width: 385px;">
                                                <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                                <p style="padding-left: 30px; text-align: left;">
                                                    Regarding the possibility of continuing treatment beyond 16 cycles for patients
                                    who do not achieve SD or better, Takeda cannot endorse a regimen that differs from
                                    that specified in the licence.
                                                </p>
                                                <br />

                                            </div>
                                        </div>
                                        <div style="width: 45%; margin-top: -80px; margin-right: -30px;">
                                            <img src="img/pdf8img1.png" data-class="fadeIn" id="o2slide4img3" style="display: none; margin-bottom: -22px; margin-top: 97px; position: relative;" />
                                        </div>
                                    </div>
                                </div>
                            </div>
                            <div style="width: 45%; float: right; margin-top: -21px; margin-right: -30px;">
                                <img src="img/S6P1.png" data-class="fadeIn" id="o2slide4img2a" style="width: 180px; display: none; margin-bottom: 9px; margin-top: 25px;" />
                                <img src="img/S4P1.png" data-class="fadeIn" id="o2slide4img2" style="width: 180px; display: none; margin-bottom: 27px; margin-top: 49px;" />

                                <img src="img/pdf8img2.png" data-class="fadeIn" id="o2slide4img3a" style="display: none;" />
                            </div>
                            <!--<div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="o2slide5img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none;" />
                                <div class="text" style="margin-left: 38px;">
                                    <br />
                                    <div data-class="fadeIn" id="o2s5txt1" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            In summary, responses were seen in the pivotal trials following up to 1 year of
                                    therapy, highlighting the importance of continuing treatment up to <b>16 cycles which
                                    is approximately equivalent to 1 year of treatment.</b>
                                        </p>
                                        <br />

                                    </div>
                                    <div data-class="fadeIn" id="o2s5txt2" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            Regarding the possibility of continuing treatment beyond 16 cycles for patients
                                    who do not achieve SD or better, Takeda cannot endorse a regimen that differs from
                                    that specified in the licence.
                                        </p>
                                        <br />

                                    </div>
                                </div>
                            </div>-->


                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="o2slide7img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; display: none;" />
                                <div class="text" style="margin-left: 38px;">
                                    <br />
                                    <div data-class="fadeIn" id="o2s7txt1" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            ADCETRIS was generally well tolerated in patients with either HL or sALCL, and most drug-related adverse events were managed through standard supportive care. The most common events were typically grade 1 or 2.<sup>2,3</sup>

                                        </p>
                                    </div>
                                        <div data-class="fadeIn" id="o2s7txt1a" style="display: none;">
                                            <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                            <p style="padding-left: 30px; text-align: left;">
                                                The optimal duration of therapy should strike a balance between maintaining tumour control and minimising toxicity, which may be best achieved with rational application of dose delays and dose reductions if toxicity develops.

                                            </p>
                                            <br />
                                        </div>
                                </div>
                            </div>
                            <div style="width: 45%; float: right; margin-right: -30px; margin-top: -10px;">
                                <img src="img/S6P1.png" data-class="fadeIn" id="o2slide7img2a" style="width: 180px; display: none; margin-bottom: 4px; margin-top: 25px;" />
                                <img src="img/S4P1.png" data-class="fadeIn" id="o2slide7img2" style="width: 180px; display: none; margin-bottom: 9px; margin-top: 25px;" />
                            </div>
                        </div>
                    </div>
                </div>
                <div id="Obj3" style="display: none;">

                    <div id="Obj3ref" style="display: none;" class="Obj3ref">
                        <b>No References</b><br />
                    </div>


                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div class="playBody">
                        </div>
                    </div>

                </div>
                <div id="slide3" style="display: none;" class="slide3ref">

                    <div id="slide3ref" style="display: none;" class="slide3ref">
                        <!--<b>No References</b><br />-->
                        <ol>
                            <li>
                                ADCETRIS®. Summary of Product Characteristics. 22 August 2014. Available at European Medicines Agency Web site http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002455/WC500135055.pdf. Accessed on 26 June 2015.

                            </li>
                            <li>
                                Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, et al,. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. <i>J Clin Oncol</i>. 2012 Jun 20;30(18):2183-9.

                            </li>
                            <li>
                                Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. <i>J Clin Oncol</i>. 2012;30(18):2190-6.

                            </li>
                        </ol>
                    </div>


                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">


                        <div class="playBody" style="margin-top: 10px; overflow: hidden;">
                            <div data-class="fadeInDown" class="breakout" style="display: none; margin-left: 30px;  text-align: center;"
                                id="S3txt1">
                                <p style="padding-left: 40px; font-size: 20px;">
                                    Objection 3
                                    <br />
                                    “What are the main criteria for continuing ADCETRIS treatment in the 8-16 dosage cycles stated in the licence? Is there any evidence that continuation of ADCETRIS will lead to a better response?”


                                </p>
                            </div>
                            <div>
                                <img src="img/S0BG1.png" data-class="fadeIn" id="O3slide0img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />

                                <img src="img/O3txt0.png" data-class="fadeIn" id="O3slide0img2" style="display: none; width: 198px; float: right; margin-right: 366px; position: relative; margin-top: 10px;" />
                            </div>
                            <div>
                                <img src="img/S1BG1.png" data-class="fadeIn" id="O3slide0img3" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />

                                <img src="img/O3txt1.png" data-class="fadeIn" id="O3slide0img4" style="display: none; width: 198px; float: right; margin-right: 366px; position: relative; margin-top: 10px;" />
                            </div>

                            <div>
                                <div>
                                    <img src="img/S2BG2.png" data-class="fadeIn" id="O3slide2img2" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px; height: 514px;" />
                                </div>


                                <p id="O3txt1" style="margin-left: 140px; padding-top: 78px; color: #FFF; display: none; position: relative; width: 658px;">
                                    You can seek further clarification to better understand the query. The following are a few questions you may ask:

                                </p>

                                <ul style="margin-left: 60px; padding-top: 30px; width: 710px;">
                                    <div data-class="fadeIn" id="O3txt2" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">What treatment goals are most important to you and your patient?</li>

                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="O3txt3" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">What criteria are most important to you when deciding on continuing treatment? </li>

                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="O3txt4" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">What barriers are there to continuing therapy into the licensed minimum period of 8 cycles, up to the maximum of 16 cycles?   </li>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="O3txt5" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">What sort of response or duration of response are you looking for from a treatment?  </li>
                                        <br />
                                        <br />
                                    </div>
                                </ul>


                            </div>
                            <div>
                                <img src="img/O3txt2.png" data-class="fadeIn" id="O3Slide3img1" style="display: none; width: 217px; margin-left: 386px; margin-top: -20px; position: relative;" />
                            </div>

                            <div>
                                <img src="img/O3txt3.png" data-class="fadeIn" id="O3Slide4img1" style="display: none; width: 223px; margin-left: 380px; margin-top: -31px; position: relative;" />
                            </div>
                            <div>
                                <img src="img/O3txt3b.png" data-class="fadeIn" id="O3Slide4img1a" style="display: none; width: 215px; margin-left: 385px; margin-top: -30px; position: relative;" />
                            </div>
                            <div>
                                <img src="img/S1BG1.png" data-class="fadeIn" id="O3Slide4img2" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />
                            </div>
                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="O3Slide5img0" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none; height: 200px;" />
                                <div class="text" style="margin-left: 25px;">
                                    <div data-class="fadeIn" id="O3Slide5txt1" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            In the two pivotal trials with HL and sALCL patients, the median time to CR was 12 weeks and 11.9 weeks respectively and <b>there was a wide range of time to CR – up to one year after treatment had started.</b><sup>2,3</sup>
                                        </p>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="O3Slide5txt2" style="display: none; margin-top: -26px; width: 386px; margin-left: -10px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            While many patients showed a relatively fast response to treatment, <b>some were shown to respond later, which reinforces the rationale of continuing treatment for at least 8 cycles, and up to 16 cycles</b> (approximately 1 year treatment time) if no progression is detected and there is no unacceptable toxicity.<sup>1</sup> 
                                        </p>
                                    </div>
                                    <div data-class="fadeIn" id="O3Slide5txt3" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            There has been no formal evaluation of the number of treatment cycles and level or duration of response, and the use of regimens with a minimum of fewer than 8 cycles is of uncertain outcome.
                                        </p>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="O3Slide5txt4" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            Regarding the possibility of continuing treatment beyond 16 cycles for patients who achieve stable disease or better, Takeda cannot endorse a regimen that differs from that specified in the licence.
                                        </p>
                                    </div>



                                </div>
                                <div>
                                    <img src="img/pdf8img1.png" data-class="fadeIn" id="O3Slide5img1a" style="display: none; margin-bottom: 9px; margin-top: 20px; margin-left: 93px;" />
                                </div>
                            </div>

                            <div style="width: 45%; float: right; margin-top: -21px; margin-right: -30px;">


                                <img src="img/S4P1.png" data-class="fadeIn" id="O3Slide5img1b" style="width: 180px; display: none; margin-bottom: 33px; margin-top: 37px;" />
                                <img src="img/pdf8img2.png" data-class="fadeIn" id="O3Slide5img2" style="display: none;" />

                            </div>

                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="O3slide6img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none;" />
                                <div class="text" style="margin-left: 38px;">
                                    <br />
                                    <div data-class="fadeIn" id="O3slide6img2" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            In the absence of unacceptable toxicity, ADCETRIS should always be continued for at least 8 cycles, up to a maximum of 16 cycles,<sup>1</sup> as some patients will show a late response.</p>
                                    </div>
                                    <div data-class="fadeIn" id="O3slide6img2a" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            The optimal duration of therapy balances maintaining disease control and maximising tolerability. ADCETRIS is generally well-tolerated, with adverse events primarily grade 1 or 2, and peripheral neuropathy manageable through dose modification.<sup>1</sup>
                                        </p>
                                    </div>


                                </div>
                            </div>
                            <div style="width: 45%; float: right; margin-top: -21px; margin-right: -30px;">
                                <img src="img/S6P1.png" data-class="fadeIn" id="O3s6txt1" style="width: 180px; display: none; margin-bottom: 9px; margin-top: 25px;" />
                                <img src="img/S4P1.png" data-class="fadeIn" id="O3s6txt2" style="width: 180px; display: none; margin-bottom: 9px; margin-top: 25px;" />
                            </div>

                        </div>
                    </div>

                </div>
                <div id="Obj4" style="display: none;">

                    <div id="Obj4ref" style="display: none;" class="Obj4ref">
                        <b>No References</b><br />
                    </div>


                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div class="playBody">
                        </div>
                    </div>

                </div>
                <div id="slide4" style="display: none;" class="slide1ref">
                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div id="slide4ref" style="display: none;" class="slide4ref">
                            <!--<b>No References</b><br />-->
                            <ol>
                                <li>Eichenauer DA, Engert A, André M, et al. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann. Oncol</i>. 2014;25 Suppl 3:iii70-5. doi:10.1093/annonc/mdu181.
</li>
                                <li>Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. <i>J. Natl. Compr. Canc. Netw.</i> 2012;10(5):589-97.
</li>
                                <li>Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, et al,. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. <i>J Clin Oncol</i>. 2012 Jun 20;30(18):2183-9.
</li>
                                <li>Gopal AK, et al. Poster abstract no. 4382 presented at American Society of Hematology, December 2013, New Orleans, LA, USA.
</li>
                            </ol>
                        </div>
                        <div class="playBody" style="margin-top: 10px; overflow: hidden;">
                            <div data-class="fadeInDown" class="breakout" style="display: none; margin-left: 30px; text-align: center;"
                                id="S4txt1">
                                <p style="padding-left: 40px; font-size: 20px;">
                                    Objection 4
                                    <br />
                                    “European treatment guidelines for Hodgkin lymphoma indicate several multi-agent regimens followed by ASCT, gemcitabine-based chemotherapy, novel single agents and/or regional radiotherapy: ADCETRIS is not included.”



                                </p>
                            </div>
                            <div>
                                <img src="img/S0BG1.png" data-class="fadeIn" id="o4slide0img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />
                                <img src="img/O4Doc1.png" data-class="fadeIn" id="o4slide0img2" style="display: none; width: 228px; float: right; margin-right: 352px; position: relative; margin-top: 10px;" />
                            </div>
                            <div>

                                <img src="img/S1BG1.png" data-class="fadeIn" id="o4slide1img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />


                                <img src="img/O4txt2.png" data-class="fadeIn" id="o4slide1img2" style="display: none; width: 220px; float: right; margin-right: 354px; position: relative; margin-top: 10px;" />
                            </div>

                            <div>
                                <div>
                                    <img src="img/S2BG2.png" data-class="fadeIn" id="o4slide2img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px; height: 514px;" />
                                </div>
                                <p id="o4txt1" style="margin-left: 140px; padding-top: 78px; color: #FFF; display: none; position: relative; width: 663px;">
                                    You need to find out if your customer is unwilling to prescribe ADCETRIS until it
                                is included in the guidelines.
                                <br />
                                    You may want to confirm your local treatment guidelines and also ask further questions
                                to clearly identify the concerns. The following are a few questions you may ask.
                                </p>
                                <ul style="margin-left: 60px; padding-top: 20px; width: 580px;">
                                    <div data-class="fadeIn" id="o4txt2" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">As this is a new treatment, what is the main unmet need you
                                        have for your difficult-to-treat patients?</li>
                                        <br />
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o4txt3" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">What is your main interest in this new treatment?</li>
                                        <br />
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o4txt4" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">What is your main area of concern?</li>
                                    </div>
                                </ul>
                            </div>
                            <div>
                                <img src="img/O4txt3.png" data-class="fadeIn" id="o4slide3img1" style="display: none; width: 223px; margin-left: 381px; margin-top: -20px; position: relative;" />

                            </div>
                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">

                                <img id="o4slide4img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none;" />

                                <div id="o4boxtxt1" class="text" style="margin-left: 38px; display: none;">

                                    <div data-class="fadeIn">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            The European Society for Medical Oncology (ESMO) examines evidence based on published data.
                                        </p>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                          The ESMO guidelines for Hodgkin lymphoma were produced in 2011 and were published before data for ADCETRIS was published , and so ADCETRIS is not included. The updated guidelines published September 2014 identify ADCETRIS as an option in patients with relapsed disease failing ASCT.<sup>1</sup>                                        </p>
                                    </div>
                                </div>




                            </div>


                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">

                                <img id="o4s4img2" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none;" />

                                <div id="o4boxtxt2" class="text" style="margin-left: 38px; display: none;">

                                    <div data-class="fadeIn">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            The National Comprehensive Cancer Network (NCCN) guidelines published in 2012 and later recommend treatment with ADCETRIS for both relapsed/refractory Hodgkin lymphoma and sALCL.<sup>2</sup>
                                        </p>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            Also, other current treatment options, including chemotherapy, radiotherapy and allogeneic-SCT, are associated with high rates of toxicity or are limited by donor availability and the high risk of treatment-related mortality.
                                        </p>
                                    </div>
                                </div>




                            </div>


                            <div style="width: 45%; float: right; margin-top: -500px; margin-right: -35px;">
                                <img src="img/S6P1.png" data-class="fadeIn" id="o4slide4img2a" style="width: 180px; display: none; margin-bottom: 9px; margin-top: 25px;" />
                                <img src="img/S4P1.png" data-class="fadeIn" id="o4slide4img2" style="width: 180px; display: none; margin-bottom: 9px; margin-top: 500px;" />
                                <img src="img/O4box1.png" data-class="fadeIn" id="o4slide4img3" style="width: 330px; display: none;" />

                                <img src="img/O4box2.png" data-class="fadeIn" id="o4slide4img3a" style="width: 330px; display: none;    margin-top: 10px;" />


                            </div>

                            <div style="width: 45%; float: right; margin-top: -21px; margin-right: -30px;">
                                <img src="img/S6P1.png" data-class="fadeIn" id="o4slide5img2a" style="width: 180px; display: none; margin-bottom: 5px; margin-top: 25px;" />

                            </div>


                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="o4slide5img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none; height: 200px;" />
                                <div class="text" style="margin-left: 25px;">
                                    <div data-class="fadeIn" id="o4s5txt1" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            In the pivotal Hodgkin lymphoma study, an overall response rate (ORR) of 75% and complete response of 34% was    observed in patients that were heavily pre-treated and highly refractory.<sup>3</sup>
                                        </p>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o4s5txt2" style="display: none; margin-top: -26px; width: 386px; margin-left: -10px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            After three years’ follow-up, median OS was 40.5 months.<sup>4</sup>
                                        </p>
                                    </div>
                                    <div data-class="fadeIn" id="o4s5txt3" style="display: none; margin-top: -20px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            So, ADCETRIS has been granted a marketing authorisation as it fulfils an unmet medical need, and the benefits of immediate availability outweigh the risk of waiting for additional data. It also has been included recently as a treatment option in the ESMO guidelines
                                        </p>
                                        <br />
                                    </div>




                                </div>
                                <div>
                                    <img src="img/O4G1.png" data-class="fadeIn" id="o4slide5img2" style="display: none; margin-bottom: 9px; margin-top: 20px; margin-left: 93px;" />
                                </div>
                            </div>

                            <div style="width: 45%; float: right; margin-top: -21px; margin-right: -30px;">


                                <img src="img/S4P1.png" data-class="fadeIn" id="o4slide5img3a" style="width: 180px; display: none; margin-bottom: 33px; margin-top: 37px;" />
                                <img src="img/pdf9img1.png" data-class="fadeIn" id="o4slide5img3" style="width: 347px; display: none;" />

                            </div>










                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="slide7img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: -45px; display: none;" />
                                <div class="text" style="margin-left: 38px; margin-top: -22px;">
                                    <br />
                                    <div data-class="fadeIn" id="o4s7txt1" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            Regarding the possibility of continuing treatment beyond 16 cycles for patients who achieve stable disease or better, Takeda cannot endorse a regimen that differs from that specified in the licence.
                                        </p>
                                        <br />
                                    </div>



                                </div>
                            </div>
                            <div style="width: 45%; float: right; margin-right: -30px; margin-top: -10px;">
                                <img src="img/S6P1.png" data-class="fadeIn" id="slide7img2a" style="width: 180px; display: none; margin-bottom: 4px; margin-top: -47px;" />
                                <img src="img/S6G1.png" data-class="fadeIn" id="slide7img3a" style="width: 180px; display: none; margin-bottom: -22px;" />
                                <img src="img/S4P1.png" data-class="fadeIn" id="slide7img2" style="width: 180px; display: none; margin-bottom: 9px; margin-top: -35px;" />

                            </div>

                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="o4slide8img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: -45px; display: none;" />
                                <div class="text" style="margin-left: 38px; margin-top: -22px;">
                                    <br />
                                    <div data-class="fadeIn" id="o4s8txt1" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            In the absence of unacceptable toxicity, ADCETRIS should always be continued for at least 8 cycles, up to a maximum of 16 cycles, as some patients will show a late response.
                                        </p>
                                    </div>
                                    <div data-class="fadeIn" id="o4s8txt2" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            The optimal duration of therapy balances maintaining disease control and maximising tolerability. ADCETRIS is generally well-tolerated, with adverse events primarily grade 1 or 2, and peripheral neuropathy manageable through dose modification.
                                        </p>
                                    </div>



                                </div>
                            </div>
                            <div style="width: 45%; float: right; margin-right: -30px; margin-top: -10px;">
                                <img src="img/S6P1.png" data-class="fadeIn" id="o4slide7img4" style="width: 180px; display: none; margin-bottom: 4px; margin-top: -47px;" />

                                <img src="img/S4P1.png" data-class="fadeIn" id="o4slide7img5" style="width: 180px; display: none; margin-bottom: 9px; margin-top: -35px;" />

                            </div>


                        </div>
                    </div>
                </div>
                <div id="Obj5" style="display: none;">
                    <!--Body -->
                    <!--<div class="topic-bar">
                        <div id="topic-title">Learning objectives</div>
                     </div>-->
                    <div id="Obj5ref" style="display: none;" class="Obj5ref">
                        <b>No References</b><br />
                    </div>
                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div class="playBody">
                        </div>
                    </div>
                </div>
                <div id="slide5" style="display: none;" class="slide1ref">
                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div id="slide5ref" style="display: none;" class="slide5ref">
                            <!--<b>No References</b><br />-->
                            <ol>
                                <li>
                                    ADCETRIS®. Summary of Product Characteristics. 22 August 2014. Available at European Medicines Agency Web site http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002455/WC500135055.pdf. Accessed on 26 June 2015.

                                </li>
                                <li>
                                    Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, et al,. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.<i> J Clin Oncol</i>. 2012 Jun 20;30(18):2183-9.

                                </li>
                               
                            </ol>
                        </div>
                        <div class="playBody" style="margin-top: 10px; overflow: hidden;">
                            <div data-class="fadeInDown" class="breakout" style="display: none; margin-left: 30px; 
 text-align: center;"
                                id="S5txt1">
                                <p style="padding-left: 40px; font-size: 20px;">
                                    Objection 5
                                    <br />
                                    “There appears to be a clear benefit from achieving CR in terms of duration of benefit in Hodgkin lymphoma patients. However, patients with PR had only a short duration of response: is there value in treating these patients using my budget?”


                                </p>
                            </div>
                            <div>
                                <img src="img/S0BG1.png" data-class="fadeIn" id="o5s32img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />
                                <img src="img/S5txt0.png" data-class="fadeIn" id="o5s32img2" style="display: none; width: 218px; float: right; margin-right: 367px; position: relative; margin-top: 10px; left: 8px;" />
                                <img src="img/S1BG1.png" data-class="fadeIn" id="o5s32img2a" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />
                                <img src="img/S5txt1.png" data-class="fadeIn" id="o5s32img3" style="display: none; width: 226px; float: right; margin-right: 353px; position: relative; margin-top: 10px;" />
                            </div>
                            <div>
                                <div>
                                    <img src="img/S2BG2.png" data-class="fadeIn" id="o5s33img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px; height: 514px;" />
                                </div>
                                <p id="o5s33txt1" style="margin-left: 100px; padding-top: 60px; max-width: 727px; color: #FFF; position: relative; display: none;">
                                    Establish the treatment goals of your customer. His/her query may relate to an older
                                    patient with comorbidities, or a young patient with fewer comorbidities: therefore
                                    the duration of response, from the doctor’s perspective, may represent differing
                                    levels of benefit and value for each patient.
                                </p>

                                <p id="o5s33txt2" style="margin-left: 140px; padding-top: 78px; color: #FFF; display: none; position: relative;">
                                    You may consider asking the following questions to clarify and understand
                                </p>
                                <ul style="margin-left: 60px; padding-top: 20px; width: 580px;">
                                    <div data-class="fadeIn" id="o5s33txt3" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">What type of patient are you thinking of?</li>
                                        <br />

                                    </div>
                                    <div data-class="fadeIn" id="o5s33txt4" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">What are the treatment goals you set for your patient? </li>
                                        <br />

                                    </div>
                                    <div data-class="fadeIn" id="o5s33txt5" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">Which sort of patient would you consider as being most appropriate
                                        for this treatment?</li>
                                    </div>
                                </ul>
                            </div>

                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="o5slide34img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none; height: 200px;" />
                                <div class="text" style="margin-left: 25px;">
                                    <div data-class="fadeIn" id="o5s34txt1" style="display: none; margin-top: -29px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 27px; text-align: left;">
                                            ADCETRIS is indicated for adult patients who have disease that has not responded to previous treatments, and for whom limited treatments remain. These patients may also have a poor quality of life. High rates of clinical response and PFS have been observed with use of ADCETRIS in such patients.<sup>1,2</sup>

                                        </p>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o5s34txt2" style="display: none; margin-top: -26px; width: 386px; margin-left: -10px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            The partial response (PR) achieved with ADCETRIS may likely be the first time the patient achieved a response.  A median PFS of 5.1 months and 3 days , as observed in the pivotal trial with HL, for a patient who achieves PR may be a long time for that particular patient.


                                        </p>
                                    </div>
                                    <div data-class="fadeIn" id="o5s34txt3" style="display: none; margin-top: -30px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            It is also worthy to note that, in a significant number of patients in the pivotal HL trial, clinical responses were associated with a reduction in disease symptoms and a reduction in tumour size.<sup>1</sup> 77% patients who experienced B-symptoms at baseline achieved resolution of symptoms.<sup>1</sup>

                                        </p>
                                        <br />
                                    </div>
                                    <div id="o5s34txt4" style="display: none; margin-top: -20px;" class="fadeIn">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 25px;">
                                            These observations associated with ADCETRIS can help with quality of life for your
                                    patients.
                                        </p>
                                    </div>




                                </div>
                                <div>
                                    <img src="img/o5S34G2.png" data-class="fadeIn" id="o5s34img5" style="display: none; margin-bottom: 9px; margin-top: 20px; margin-left: 93px;" />
                                </div>
                            </div>

                            <div style="width: 45%; float: right; margin-top: -21px; margin-right: -30px;">

                                <img src="img/S4P1.png" data-class="fadeIn" id="o5s34img3" style="width: 180px; display: none; margin-bottom: 20px; margin-top: 37px;" />

                                <img src="img/o5S34G1.png" data-class="fadeIn" id="o5s34img4" style="display: none;margin-top: 12px;" />

                            </div>




                            <div class="image" style="width: 44%; margin-left: 62px;">
                                <img id="o5slide35img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none; float: right;" />
                                <div class="text" style="margin-left: -20px;">

                                    <div id="o5s35txt1" style="display: none; margin-left: -20px; margin-top: -5px;" class="fadeIn">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 25px;">
                                            So, in a significant number of patients, ADCETRIS offers a durable response. In
                                    addition, ADCETRIS is not associated with high levels of toxicity, treatment-related
                                    mortality or the use of supportive treatments. If you are trying to prolong the
                                    life of your patient with the best possible quality of life during that time, ADCETRIS
                                    has a benefit over high-dose chemotherapy.<sup>1</sup>
                                        </p>
                                    </div>
                                </div>
                            </div>
                            <div style="width: 45%; float: right; margin-top: -21px; margin-right: -30px;">

                                <img src="img/S6P1.png" data-class="fadeIn" id="o5s35rep1" style="width: 180px; display: none; margin-bottom: 20px; margin-top: -700px;" />



                            </div>
                        </div>
                    </div>
                </div>
                <div id="Obj6" style="display: none;">

                    <div id="Obj6ref" style="display: none;" class="Obj6ref">
                        <b>No References</b><br />
                    </div>


                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div class="playBody">
                        </div>
                    </div>

                </div>


                <div id="slide6" style="display: none;" class="slide1ref">
                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div id="slide6ref" style="display: none;" class="slide6ref">
                            <!--<b>No References</b><br />-->
                            <ol>
                                <li>
                                    Gibb A, Jones C, Bloor A, et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica 2013;98(4):611-4. doi:10.3324/haematol.2012.069393.

                                </li>
                                <li>
                                    Rothe A, Sasse S, Goergen H, et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. <i>Blood</i> 2012;120(7):1470-2. doi:10.1182/blood-2012-05-430918.

                                </li>
                                <li>
                                    Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, et al,. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. <i>J Clin Oncol.</i> 2012 Jun 20;30(18):2183-9.

                                </li>
                            </ol>
                        </div>
                        <div class="playBody" style="margin-top: 10px; overflow: hidden;">
                            <div data-class="fadeInDown" class="breakout" style="display: none; margin-left: 30px; text-align: center;"
                                id="S6text1">
                                <p style="padding-left: 40px; font-size: 20px;">
                                    Objection 6
                                    <br />
                                    “Can we expect to see the same response rates in real life or was the data/patient selection biased?”



                                </p>
                            </div>
                            <div>
                                <img src="img/S0BG1.png" data-class="fadeIn" id="o6slide0img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />
                                <img src="img/O6txt1.png" data-class="fadeIn" id="o6slide0img2" style="display: none; width: 233px; float: right; margin-right: 350px; position: relative; margin-top: 10px;" />
                            </div>
                            <div>
                                <img src="img/S1BG1.png" data-class="fadeIn" id="o6slide1img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />
                                <img src="img/O6txt2.png" data-class="fadeIn" id="o6slide1img2" style="display: none; width: 221px; float: right; margin-right: 355px; position: relative; margin-top: 10px;" />
                            </div>
                            <div>
                                <div>
                                    <img src="img/S2BG2.png" data-class="fadeIn" id="o6slide2img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px; height: 514px;" />
                                </div>
                                <p id="o6txt1" style="margin-left: 248px; padding-top: 78px; color: #FFF; display: none; position: relative;">
                                    Establish your customer’s concerns and belief in the data.

                                </p>
                                <br />
                                <br />
                                <p id="o6txt2" style="margin-left: 140px; padding-top: 78px; color: #FFF; display: none; position: relative;">
                                    You may consider asking the following questions to clarify and understand


                                </p>
                                <ul style="margin-left: 60px; padding-top: 20px; width: 580px;">
                                    <div data-class="fadeIn" id="o6txt3" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">What type of difficult-to-treat patients are you most focused on in your question?</li>
                                        <br />
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o6txt4" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">Would you be interested in the context of these data, as we have experience closer to real life through the named patient programme (NPP)?</li>
                                        <br />
                                        <br />
                                    </div>

                                </ul>
                            </div>

                            <div class="image" style="width: 44%; float: left; margin-right: 100px; margin-top: -45px;">
                                <img id="o6slide4img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none;" />
                                <div class="text" style="margin-left: 38px;">


                                    <div data-class="fadeIn" id="o6s4txt1" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            In addition to the clinical trials conducted for marketing authorisation, Takeda made ADCETRIS available from 2010 to the medical community through named patient programs (NPPs). 
                                        </p>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o6s4txt2" style="display: none;margin-top: -14px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            The aim of NPPs is to provide access to a drug to patients who may benefit from the drug and have few other options. The NPPs are independent and cannot be influenced by Takeda.
                                        </p>
                                    </div>
                                    <div data-class="fadeIn" id="o6s4txt3" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            The patients included in an NPP would rarely meet the criteria for a clinical trial, and so NPPs can provide an indication of how ADCETRIS will behave in real life. 
                                            Let’s look at the data that have been published by the NPPs.
                                        </p>
                                        <br />
                                    </div>
                                </div>

                            </div>
                            <div style="width: 45%; float: right; margin-top: -21px; margin-right: -30px;">
                                <img src="img/S6P1.png" data-class="fadeIn" id="o6slide4img2a" style="width: 180px; display: none; margin-bottom: 9px; margin-top: -20px;" />
                                <img src="img/S4P1.png" data-class="fadeIn" id="o6slide4img2" style="width: 180px; display: none; margin-bottom: 9px; margin-top: -20px;" />
                                <img src="img/S6P1.png" data-class="fadeIn" id="o6s4R0" style="width: 180px; display: none; margin-bottom: 9px; margin-top: -20px;" />
                                <img src="img/S5P1.png" data-class="fadeIn" id="o6s4R1" style="width: 180px; margin-bottom: 9px; margin-top: -20px; display: none;" />

                            </div>

                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">

                                <img id="o6img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: -50px; display: none;" />

                                <div id="o6boxtxt1" class="text" style="margin-left: 13px; display: block; width: 425px; font-size: 7px; top: -38px; display: none;">
                                    <br />
                                    <div>
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 84px;" />
                                        <p style="width: 343px; margin-top: 20px; padding-left: 25px;">
                                            In an NPP in the UK, 24 patients; 19 with Hodgkin lymphoma and 5 with sALCL, were treated with ADCETRIS. Efficacy data were reported for all patients and at a median follow-up of 12.9 months, were still alive.<sup>1</sup> 
                                        </p>
                                        <br />
                                    </div>
                                </div>


                                <div id="o6boxtxt2" class="text" style="margin-left: 13px; margin-top: 88px; display: none;">
                                    <br />
                                    <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 83px;" />
                                    <p style="padding-left: 25px;">
                                        The overall response rate <b>(ORR) for HL was 72%</b> and <b>median PFS</b> was <b>5.1 months.</b> A CR rate of 25%, independent of prior ASCT status, was reported.<sup>1</sup>
                                    </p>
                                    <br />
                                </div>

                                <div id="o6boxtxt2a" class="text" style="margin-left: 37px; margin-top: -60px; display: none;">
                                    <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 84px;" />
                                    <p style="padding-left: 25px;">
                                        In a German study, Hodgkin lymphoma patients achieved an <b>ORR of 60%</b> and the <b>median PFS</b> was <b>8 months.</b> These results compare well with the data from the ADCETRIS clinical trials that showed an <b>ORR of 75%</b> and a <b>median PFS</b> of <b>5.6 months.</b><sup>2,3</sup>
                                    </p>
                                    <br />
                                </div>
                                <div id="o6boxtxt3" class="text" style="margin-left: 39px; width: 425px; margin-top: 131px; font-size: 11px; display: none;">
                                    <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 48px;" />
                                    <p style="width: 343px; padding-left: 25px;">
                                        In summary, the data suggest that you can expect to see responses in real life that are comparable with the clinical trial data, and of considerable benefit to your patients. 
                                    </p>
                                    <br />
                                </div>

                                <div id="o6boxtxt4" class="text" style="margin-left: 13px; display: none; width: 425px; margin-top: -50px; max-width: 398px;">
                                    <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                    <p style="padding-left: 25px;">
                                        So, the efficacy outcomes in published NPPs and the pivotal trials of ADCETRIS were comparable.
In addition, in both the UK and German NPP published results, the toxicity profile of ADCETRIS was also reported to be very similar to the published data, which provides confidence for both you and your patients.
                                    </p>
                                    <br />
                                </div>
                            </div>
                        </div>



                        <div style="width: 44%; float: right; margin-top: -160px; margin-right: -35px;">

                            <!-- <img src="img/S5P1.png" data-class="fadeIn" id="o6s4Rep3" style="width: 180px;margin-bottom: 33px;margin-top: -312px; display:none;" />-->
                            <img src="img/O6box1.png" data-class="fadeIn" id="o6s4R2" style="width: 330px; margin-top: -58px; margin-left: -32px; display: none;" />

                            <img src="img/O6box2.png" data-class="fadeIn" id="o6s4R3" style="width: 330px; margin-top: -85px; display: none;" />

                            <img src="img/O6box3.png" data-class="fadeIn" id="o6s4R4" style="width: 330px; display: none;" />


                        </div>
                        <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                            <img id="o6p1img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none;" />
                            <!--<div class="text" style="">-->



                            <!--</div>-->

                        </div>
                        <!-- <div style="width: 45%; float: right; margin-top: -21px; margin-right: -30px;">
                            <img src="img/S6P1.png" data-class="fadeIn" id="o6a" style="width: 180px;
                                display: none; margin-bottom: 9px; margin-top: 25px;" />
                            <img src="img/S4P1.png" data-class="fadeIn" id="o6b" style="width: 180px;
                                display: none; margin-bottom: 9px; margin-top: 25px;" />
                           
                        </div>-->


                    </div>

                </div>

                <div id="Obj7" style="display: none;">
                    <!-- <div class="topic-bar">
                        <div id="topic-title">Title</div>
                    </div>-->
                    <!--Body -->
                    <!--<div class="topic-bar">
                        <div id="topic-title">Learning objectives</div>
                     </div>-->
                    <div id="Obj7ref" style="display: none;" class="Obj7ref">
                        <b>No References</b><br />
                    </div>

                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div class="playBody">
                        </div>
                    </div>
                </div>
                <div id="slide7" style="display: none;" class="slide7ref">
                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div id="slide7ref" style="display: none;" class="slide7ref">
                            <!--<b>No References:</b><br />-->
                            <ol>
                                <li>
                                    ADCETRIS®. Summary of Product Characteristics. 22 August 2014. Available at European Medicines Agency Web site http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002455/WC500135055.pdf. Accessed on 26 June 2015.
                                </li>
                            </ol>
                        </div>
                        <div class="playBody" style="margin-top: 10px; overflow: hidden;">
                            <div data-class="fadeInDown" class="breakout" style="display: none; margin-left: 30px; text-align: center;"
                                id="obj7s42txt1">
                                <p style="padding-left: 40px; font-size: 20px;">
                                    Objection 7
                                    <br />
                                    The data for transplant-ineligible patients are inconclusive. Why should I trust the data?”


                                </p>
                            </div>
                            <div>
                                <img src="img/S0BG1.png" data-class="fadeIn" id="o7s42img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />
                                <img src="img/o7s42txt1.png" data-class="fadeIn" id="o7s42img2" style="display: none; width: 214px; float: right; margin-right: 364px; position: relative; margin-top: 10px;" />
                            </div>
                            <div>
                                <img src="img/S1BG1.png" data-class="fadeIn" id="o7s42img3" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />
                                <img src="img/o7s42txt2.png" data-class="fadeIn" id="o7s42img4" style="display: none; width: 224px; float: right; margin-right: 355px; position: relative; margin-top: 10px;" />
                            </div>
                            <div>
                                <div>
                                    <img src="img/S2BG2.png" data-class="fadeIn" id="o7s43img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px; height: 514px;" />
                                </div>
                                <p id="o7s43txt1" style="margin-left: 140px; padding-top: 78px; color: #FFF; display: none; position: relative;">
                                    Establish why the customer mistrusts the data to better understand their concern
                                </p>
                                <p id="o7s43txt2" style="margin-left: 140px; padding-top: 78px; color: #FFF; display: none; position: relative;">
                                    You may consider asking the following questions to clarify and understand
                                </p>
                                <ul style="margin-left: 60px; padding-top: 20px; width: 580px;">
                                    <div data-class="fadeIn" id="o7s43txt3" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">What specific concerns do you have about the data?
                                        </li>
                                        <br />

                                    </div>
                                    <div data-class="fadeIn" id="o7s43txt4" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">Would you like to look at the data for this group of patients?</li>
                                    </div>
                                    <br />
                                    <div data-class="fadeIn" id="o7s43txt5" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white; height: 68px;">What are your treatment goals for your patients considered ineligible for transplant?</li>
                                    </div>
                                </ul>
                            </div>
                            <div>
                                <img src="img/o7s45txt1.png" data-class="fadeIn" id="o7s45txt1" style="display: none; position: relative; margin-bottom: 30px; width: 220px; margin-left: 382px; margin-top: -40px;" />
                            </div>
                            <div class="image" style="width: 44%; float: left; margin-right: 100px; margin-top: -22px;">
                                <img id="o7s46img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: -5px; max-height: 490px; display: none;" />
                                <div class="text" style="margin-left: 49px; margin-top: 24px;">
                                    <br />
                                    <div data-class="fadeIn" id="o7s46txt1" style="display: none; margin-top: -50px; margin-left: -20px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 25px;">
                                            In a phase I trial and NPP, 41 patients received the recommended ADCETRIS dosing regimen, 54% (22/41) of the patients achieved an OR and 22% (9/41) achieved CR.<sup>1</sup>
                                        </p>
                                    </div>
                                    <br />
                                    <div data-class="fadeIn" id="o7s46txt2" style="display: none; margin-left: -20px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 25px;">
                                            In addition, 8 (19%) patients went on to receive a subsequent SCT<sup>1</sup> which indicates the potential for durable response in this subset of patients, who were unable to receive a transplant prior to treatment with ADCETRIS.
                                        </p>
                                    </div>
                                    <br />
                                    <div data-class="fadeIn" id="o7s46txt3" style="display: none; margin-left: -20px; margin-top: -90px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 25px;">
                                            The regulatory authority scrutinised the study data and considered that an ORR of 54% and a CR of 22% in patients not suitable for ASCT may be considered clinically relevant in itself.<sup>1</sup>
                                        </p>
                                    </div>
                                    <br />
                                    <div data-class="fadeIn" id="o7s46txt4" style="display: none; margin-left: -20px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 25px;">
                                            The regulatory authority is an independent assessor that has looked at that data and believes that ADCETRIS is a suitable treatment option for these patients.
                                        </p>
                                    </div>
                                </div>
                            </div>
                            <div style="width: 45%; float: right; margin-top: -48px; margin-right: -30px;">
                                <img src="img/S6P1.png" data-class="fadeIn" id="o7s46img2" style="width: 180px; display: none; margin-bottom: 9px; margin-top: 25px;" />
                                <img src="img/S4P1.png" data-class="fadeIn" id="o7s46img4" style="width: 180px; display: none; margin-bottom: 9px; margin-top: 25px;" />
                                <img src="img/S5P1.png" data-class="fadeIn" id="o7s46rep2" style="width: 180px; display: none; margin-bottom: 9px; margin-top: 55px;" />
                                <img src="img/o7s46g1.png" data-class="fadeIn" id="o7s46img3" style="width: 350px; margin-top: 32px; display: none;" />

                            </div>
                            <div class="image" style="width: 44%; margin-right: 65px; margin-top: -22px;">
                                <img id="o7s47img2" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none;" />
                                <div class="text" style="margin-left: 6px; margin-top: 24px;">
                                    <br />
                                    <div data-class="fadeIn" id="o7s47txt1" style="display: none; margin-top: -40px; margin-left: 30px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 25px;">
                                            So, clinically significant results have been achieved, even with transplant ineligible patients. Further data will be available in 2016 from a single arm study conducted as part of the fulfilment of a post-approval commitment.
                                        </p>
                                    </div>

                                </div>

                            </div>
                        </div>

                    </div>
                </div>
                <div id="Obj8" style="display: none;">
                    <div id="Obj8ref" style="display: none;" class="Obj8ref">
                        <b>No References</b><br />
                    </div>



                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div class="playBody">
                        </div>
                    </div>

                </div>

                <div id="slide8" style="display: none;" class="slide1ref">
                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div id="slide8ref" style="display: none;" class="slide8ref">
                            <b>No References</b><br />
                            <ol>
                                <li>Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. <i>J Clin Oncol</i>. 2012;30(18):2190-6</li>
                                <li>
                                    Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD et al. Four-year survival results from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Poster, Abstract No. 3095, American Society of Hematology, December, 2014, San Francisco, CA, USA.
                                </li>
                                <li>
                                    ADCETRIS®. Summary of Product Characteristics. 22 August 2014. Available at European Medicines Agency Web site http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002455/WC500135055.pdf. Accessed on 26 June 2015.
                                </li>
                            </ol>
                        </div>
                        <div class="playBody" style="margin-top: 10px; overflow: hidden;">
                            <div data-class="fadeInDown" class="breakout" style="display: none; margin-left: 30px;text-align: center;"
                                 id="s8txt1">
                                <p style="padding-left: 40px; font-size: 20px;">
                                    Objection 8
                                    <br />
                                    “The sALCL patient group is very small.”



                                </p>
                            </div>

                            <div>
                                <img src="img/S0BG1.png" data-class="fadeIn" id="o8slide0img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />
                                <img src="img/O8doc.png" data-class="fadeIn" id="o8slide0img2" style="display: none; width: 243px; float: right; margin-right: 351px; position: relative; margin-top: 10px;" />
                            </div>
                            <div>
                                <img src="img/S1BG1.png" data-class="fadeIn" id="o8slide1img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />
                                <img src="img/O8txt1.png" data-class="fadeIn" id="o8slide1img2" style="display: none; width: 224px; float: right; margin-right: 355px; position: relative; margin-top: 10px;" />
                            </div>
                            <div>
                                <div>
                                    <img src="img/S2BG2.png" data-class="fadeIn" id="o8slide2img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px; height: 514px;" />
                                </div>
                                <p id="o8txt1" style="margin-left: 140px; padding-top: 78px; color: #FFF; display: none; position: relative; width: 690px;">
                                    You can get a better understanding of the customer’s inquiry by trying to gain insight into their particular concern. The following are a few questions you may ask
                                </p>
                                <ul style="margin-left: 60px; padding-top: 20px; width: 769px;">
                                    <div data-class="fadeIn" id="o8txt2" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">Are you referring to the general number of patients with sALCL, or the number of patients in the ADCETRIS study?</li>
                                        <br />
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o8txt3" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">What are your treatment goals with your sALCL patients?</li>
                                        <br />
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o8txt4" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">So I can answer your question fully, do you have any concerns about using ADCETRIS with sALCL patients that would prevent you from using it with appropriate patients?</li>
                                    </div>
                                </ul>
                            </div>

                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="o8slide4img1" alt="" src="img/S4BG1.png" style="width: 101%; margin-left: 62px; margin-top: 5px; display: none;" />
                                <div class="text" style="margin-left: 25px; margin-top: -46px; width: 358px;">
                                    <div data-class="fadeIn" id="o8s4txt1" style="display: none;">
                                        <br />
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 40px;" />
                                        <p style="">
                                            As you know, from an epidemiological perspective, the Hodgkin lymphoma group is larger than the sALCL group.

                                        </p>
                                    </div>
                                    <br />
                                    <div data-class="fadeIn" id="o8s4txt2" style="display: none; margin-top: -17px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 101px;" />
                                        <p style="">
                                            The ADCETRIS pivotal sALCL study included 58 patients and was an international trial in heavily pre-treated relapsed or refractory patients.<sup>1</sup> It was felt that in general, the demographics reflect the characteristics of patients with sALCL.
                                        </p>
                                    </div>
                                    <br />
                                    <div data-class="fadeIn" id="o8s4txt3" style="display: none; margin-top: -20px; width: 369px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 220px;" />
                                        <p style="">
                                            In the trial, an objective response rate of 86% was attained and 59% of the patients achieved a complete response.<sup>1</sup> The latest analysis  of the four-year follow-up results  presented at ASH 2014, demonstrated that the median OS was 55.1 months.<sup>2</sup> The 4 year estimated rate of PFS and OS was similar for both ALK(-) and ALK(+) patients.<sup>2</sup> This is the largest study reported in patients with  relapsed or refractory sALCL.<sup>3</sup>

                                        </p>
                                    </div>
                                    <br />
                                    <div data-class="fadeIn" id="o8s4txt4" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 50px;" />
                                        <p style="">
                                            This means that with ADCETRIS, your sALCL patients have a treatment option with a high ORR if they are refractory or relapse following first line treatment.
                                        </p>
                                    </div>
                                    <br />
                                    <div data-class="fadeIn" id="o8s4txt5" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 84px;" />
                                        <p style="">
                                            Takeda is including as many patients as possible in the post-approval commitment trials.
                                        </p>
                                    </div>
                                </div>
                            </div>
                            <div style="width: 43%; float: right; margin-top: -130px; margin-right: -35px;">
                                <img src="img/S6P1.png" data-class="fadeIn" id="o8box1" style="width: 180px; display: none; margin-bottom: 30px; margin-top: 154px;" />
                                <img src="img/S4P1.png" data-class="fadeIn" id="o8box2" style="width: 180px; margin-bottom: 33px; margin-top: 154px; display: none;" />
                                <img src="img/O8box1.png" data-class="fadeIn" id="o8box3" style="width: 400px; margin-top: 10px; margin-left: -50px; display: none;" />

                                <img src="img/O8box1b.png" data-class="fadeIn" id="o8box4" style="width: 400px; margin-top: 10px; margin-left: -50px; display: none;" />
                                <img src="img/O8box1a.png" data-class="fadeIn" id="o8box4a" style="width: 400px; margin-top: 10px; margin-left: -50px; display: none;" />
                                <img src="img/O8box1c.png" data-class="fadeIn" id="o8box4b" style="width: 400px; margin-top: 10px; margin-left: -50px; display: none;" />
                                <img src="img/O8box1d.png" data-class="fadeIn" id="o8box5" style="width: 400px; margin-top: 10px; margin-left: -50px; display: none;" />


                            </div>

                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="o8slide5img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: -1px; display: none;" />
                                <div class="text" style="margin-left: 38px;">

                                    <div data-class="fadeIn" id="o8s5txt1" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 169px;" />
                                        <p style="">
                                            ADCETRIS is an orphan drug that has been granted a licence because it fulfils an unmet medical need. It has been shown to be a real treatment option for patients with relapsed/refractory sALCL. With time, more data will become available and will be reviewed. The European regulatory agency will review new information at least once per year.
                                        </p>
                                    </div>
                                </div>
                            </div>
                            <div style="width: 45%; float: right; margin-top: -21px; margin-right: -30px;">
                                <img src="img/S6P1.png" data-class="fadeIn" id="o8slide5img2a" style="width: 180px; display: none; margin-bottom: -21px; margin-top: 25px;" />

                                <img src="img/S4P1.png" data-class="fadeIn" id="o8slide5img2" style="width: 180px; display: none; margin-bottom: 9px; margin-top: 25px;" />

                            </div>


                        </div>
                    </div>
                </div>
                <div id="Obj9" style="display: none;">

                    <div id="Obj9ref" style="display: none;" class="Obj9ref">
                        <b>No References</b><br />
                    </div>


                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div class="playBody">
                        </div>
                    </div>

                </div>

                <div id="slide9" style="display: none;" class="slide1ref">
                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div id="slide9ref" style="display: none;" class="slide9ref">
                            <!--<b>No References</b><br />-->
                            <ol>
                                <li>Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.<i> J Clin Oncol</i>. 2012;30(18):2190-6.
</li>
                                <li>ADCETRIS®. Summary of Product Characteristics. 22 August 2014. Available at European Medicines Agency Web site http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002455/WC500135055.pdf. Accessed on 26 June 2015.
</li>
                                <li>Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD et al. Four-year survival results from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Poster, Abstract No. 3095, American Society of Hematology, December, 2014, San Francisco, CA, USA.
</li>
                            </ol>
                        </div>
                        <div class="playBody" style="margin-top: 10px; overflow: hidden;">
                            <div data-class="fadeInDown" class="breakout" style="display: none; margin-left: 30px;  text-align: center;"
                                id="s9txt1">
                                <p style="padding-left: 40px; font-size: 20px;">
                                    Objection 9
                                    <br />
                                    “There appears to be a clear benefit from achieving CR in terms of duration of response in sALCL patients. However, patients with PR had a shorter duration of response, so is there value in treating these patients?”



                                </p>
                            </div>
                            <div>
                                <img src="img/S0BG1.png" data-class="fadeIn" id="o9slide0img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />
                                <img src="img/O9doc.png" data-class="fadeIn" id="o9slide0img2" style="display: none; width: 233px; float: right; margin-right: 347px; position: relative; margin-top: 10px;" />
                            </div>
                            <div>
                                <img src="img/S1BG1.png" data-class="fadeIn" id="o9slide1img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />
                                <img src="img/O9txt1.png" data-class="fadeIn" id="o9slide1img2" style="display: none; width: 221px; float: right; margin-right: 357px; position: relative; margin-top: 10px;" />
                            </div>
                            <div>
                                <div>
                                    <img src="img/S2BG2.png" data-class="fadeIn" id="o9slide2img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px; height: 514px;" />
                                </div>
                                <p id="o9txt1" style="margin-left: 140px; padding-top: 78px; color: #FFF; display: none; position: relative; width: 676px;">
                                    Establish the treatment goals of your customer. The following are a few questions you may ask

                                </p>
                                <ul style="margin-left: 60px; padding-top: 20px; width: 580px;">
                                    <div data-class="fadeIn" id="o9txt2" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">What type of patient are you thinking of in this question?</li>
                                        <br />

                                    </div>
                                    <div data-class="fadeIn" id="o9txt3" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">What are your treatment goals for your patient?</li>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o9txt4" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">Which sort of patient would you see as being most appropriate for this treatment?</li>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o9txt5" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">What value would you expect from treatment for this type of patient?</li>
                                        <br />
                                    </div>
                                </ul>
                            </div>

                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="o9slide4img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: -12px; display: none;" />
                                <div class="text" style="margin-left: 38px; margin-top: -13px;">
                                    <div data-class="fadeIn" id="o9s4txt1" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 166px;" />
                                        <p>
                                            Data from 4 year follow up of the pivotal sALCL trial revealed that the estimated median PFS time was 20 months and the median PFS in patients who achieved PR was 4.5 months.<sup>3</sup> A median PFS of 4.5 months for a patient who achieves PR may be a long time considering that it may be the first time that the patient has achieved PR.
                                        </p>
                                    </div>
                                    <div data-class="fadeIn" id="o9s4txt2" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 112px;" />
                                        <p>
                                            In addition, resolution of all B-symptoms in 82% or 14 out of 17 patients who had B-symptoms at baseline, after a median time of 0.7 months from initiation of ADCETRIS was observed.<sup>1</sup> Also, tumour reduction occurred in 97% patients.<sup>1</sup>
                                        </p>
                                    </div>
                                    <div data-class="fadeIn" id="o9s4txt3" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 123px;" />
                                        <p>
                                            Such results can help with quality of life for your patients in the time that they have.
                                        </p>
                                    </div>


                                </div>
                            </div>
                            <div style="width: 43%; float: right; margin-top: -130px; margin-right: -35px;">
                                <img src="img/S6P1.png" data-class="fadeIn" id="o9box1" style="width: 180px; display: none; margin-bottom: 30px; margin-top: 120px;" />
                                <img src="img/S4P1.png" data-class="fadeIn" id="o9box2" style="width: 180px; margin-bottom: 33px; margin-top: 114px; display: none;" />
                                <img src="img/O9graph.png" data-class="fadeIn" id="o9box3" style="display: none;" />
                            </div>

                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="o9slide4img1a" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 0px; display: none;" />
                                <div class="text" style="margin-left: 38px; margin-top: -28px;">
                                    <div data-class="fadeIn" id="o9s4txt1a" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 80px;" />
                                        <p>
                                            ADCETRIS is indicated for small groups of patients, who have disease that has failed to respond to previous treatments, and for whom there are limited treatments remaining. 

                                        </p>
                                    </div>
                                    <div data-class="fadeIn" id="o9s4txt2a" style="display: none; margin-top: 32px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 67px;" />
                                        <p>
                                            Patients who are eligible to receive ADCETRIS may not have previously achieved PR and have a poor quality of life.

                                        </p>
                                    </div>
                                    <div data-class="fadeIn" id="o9s4txt3a" style="display: none; margin-top: 32px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 123px;" />
                                        <p>
                                            For patients such as these, ADCETRIS has been shown to give high rates of clinical response and PFS.<sup>1,2</sup>

                                        </p>
                                    </div>


                                </div>
                            </div>

                            <div style="width: 43%; float: right; margin-top: -130px; margin-right: -35px;">
                                <img src="img/S6P1.png" data-class="fadeIn" id="o9box1a" style="width: 180px; display: none; margin-bottom: 30px; margin-top: 120px;" />
                                <img src="img/S4P1.png" data-class="fadeIn" id="o9box2a" style="width: 180px; margin-bottom: 33px; margin-top: 114px; display: none;" />

                            </div>








                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="o9slide5img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none;" />
                                <div class="text" style="margin-left: 38px;">
                                    <br />
                                    <div data-class="fadeIn" id="o9s5txt1" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 210px;" />
                                        <p>
                                            So, in a significant number of patients, ADCETRIS offers a durable response, and not just for those that achieve CR. In addition, ADCETRIS is not associated with high levels of toxicity, treatment-related mortality or the need for use of supportive treatments. If your goal is to prolong the life of your patient with the best possible quality of life, ADCETRIS is a viable treatment option.
                                        </p>
                                    </div>
                                </div>
                            </div>
                            <div style="width: 45%; float: right; margin-top: -21px; margin-right: -30px;">
                                <img src="img/S6P1.png" data-class="fadeIn" id="o9slide5img2a" style="width: 180px; display: none; margin-bottom: -21px; margin-top: 25px;" />

                                <img src="img/S4P1.png" data-class="fadeIn" id="o9slide5img2" style="width: 180px; display: none; margin-bottom: 9px; margin-top: 25px;" />

                            </div>

                        </div>





                    </div>
                </div>
                <div id="Obj10" style="display: none;">

                    <div id="Obj10ref" style="display: none;" class="Obj10ref">
                        <b>No References</b><br />
                    </div>


                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div class="playBody">
                        </div>
                    </div>

                </div>


                <div id="slide10" style="display: none;" class="slide10ref">
                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div id="slide10ref" style="display: none;" class="slide10ref">
                            <!--<b>No References</b><br />-->
                            <ol>
                                <li>
                                    Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. <i>J Clin Oncol</i>. 2012;30(18):2190-6.

                                </li>
                                <li>
                                    Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD et al. Four-year survival results from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Poster, Abstract No. 3095, American Society of Hematology, December, 2014, San Francisco, CA, USA.

                                </li>
                            </ol>
                        </div>
                        <div class="playBody" style="margin-top: 10px; overflow: hidden;">
                            <div data-class="fadeInDown" class="breakout" style="display: none; margin-left: 30px;text-align: center;"
                                 id="s10txt1">
                                <p style="padding-left: 40px; font-size: 20px;">
                                    Objection 10
                                    <br />
                                    “I am concerned that there are limited data on survival with ADCETRIS in relapsed or refractory sALCL patients”




                                </p>
                            </div>
                            <div>
                                <img src="img/S0BG1.png" data-class="fadeIn" id="o10s59img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />
                                <img src="img/o10s59txt1.png" data-class="fadeIn" id="o10s59txt1" style="display: none; width: 233px; float: right; margin-right: 360px; position: relative; margin-top: 10px;" />
                            </div>
                            <div>
                                <img src="img/S1BG1.png" data-class="fadeIn" id="o10s59img2" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />
                                <img src="img/o10s59txt2.png" data-class="fadeIn" id="o10s59txt2" style="display: none; width: 227px; float: right; margin-right: 351px; position: relative; margin-top: 10px;" />
                            </div>
                            <div>
                                <div>
                                    <img src="img/S2BG2.png" data-class="fadeIn" id="o10s60img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px; height: 514px;" />
                                </div>
                                <p id="o10s60txt1" style="margin-left: 100px; padding-top: 60px; color: #FFF; display: none; position: relative; max-width: 745px;">
                                    Establish whether your customer is concerned that there is no OS data or about how the ORR reported in the sALCL trial, which is a surrogate endpoint, translates into OS or that the survival data are not good enough to warrant treatment
                                </p>
                                <p id="o10s60txt2" style="margin-left: 140px; padding-top: 50px; color: #FFF; display: none; position: relative;">
                                    You may ask the following questions to gain further clarification:
                                </p>
                                <ul style="margin-left: 60px; padding-top: 20px; width: 580px;">
                                    <div data-class="fadeIn" id="o10s60txt3" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">Are you concerned that there are no overall survival data?</li>
                                        <br />
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o10s60txt4" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">
                                            What treatment goals do you have for your patient?
                                        </li>
                                        <br />
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o10s60txt5" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">Are you concerned that the trial numbers are not high enough to produce good survival data?</li>
                                    </div>
                                </ul>
                            </div>
                            <!--<div>
            <img src="img/S3txt1.png" data-class="fadeIn" id="slide3img1" style="display: none;
                width: 230px; margin-left: 386px; margin-top: -20px; position: relative;" />
        </div>-->
                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="o10s61img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none; max-height: 490px;" />
                                <div class="text" style="margin-left: 38px;">
                                    <br />
                                    <div data-class="fadeIn" id="o10s61txt1" style="display: none; margin-top: -30px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 123px;" />
                                        <p style="padding-left: 25px;">
                                            As you are aware, ADCETRIS is indicated for a subset of patients who have disease that has failed to respond to prior treatments, and  have limited treatment options that offer substantial hope of a cure.
                                        </p>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o10s61txt2" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 25px;">
                                            Data continue to emerge as this is an orphan drug that has been granted a licence to fulfil an unmet medical need.
                                        </p>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o10s61txt3" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 123px;" />
                                        <p style="padding-left: 25px;">
                                            There are some overall survival data which we can review now.  And with time, more data will become available and will be reviewed. The regulatory agency will review new information at least once per year.
                                        </p>
                                        <br />
                                    </div>
                                </div>
                            </div>
                            <div style="width: 45%; float: right; margin-top: -21px; margin-right: -30px;">
                             
                                <img src="img/S6P1.png" data-class="fadeIn" id="o10s61rep1" style="width: 180px; display: none; margin-bottom: 32px; margin-top: 25px;" />

                            </div>
                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="o10s61img1a" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none; height: 228px;" />
                                <div class="text" style="margin-left: 38px;margin-top: -42px;">
                                    <br />


                                    <div data-class="fadeIn" id="o10s61txt4" style="display: none; margin-top: -10px;">
                                        <img id="o10s61img1a" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none; max-height: 490px;" />
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 25px;">
                                            Analysis of data from 4 years of follow-up revealed that the median overall survival was 55.1 months.<sup>2</sup>

                                        </p>
                                    </div>
                                    <div data-class="fadeIn" id="o10s61txt5" style="display: none; margin-top: 15px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 123px;" />
                                        <p style="padding-left: 25px;">
                                            The median duration of overall survival varied with the degree of response to ADCETRIS. Better degree of response to treatment was associated with better overall survival.<sup>2</sup>
                                        </p>
                                    </div>
                                </div>
                            </div>
                            <div style="width: 45%; float: left; margin-top: 10px;    margin-left: 100px;  ">
                                <img src="img/pdf9img2a.png" data-class="fadeIn" id="o10s61gra2a" style="display: none;" />
                                </div>
                                <div style="width: 45%; float: right; margin-top: -21px; margin-right: -30px;">
                                    <img src="img/S5P1.png" data-class="fadeIn" id="o10s61rep3" style="width: 180px; display: none; margin-bottom: 20px; margin-top: 25px;" />

                                    <img src="img/S4P1.png" data-class="fadeIn" id="o10s61rep2" style="width: 180px; display: none; margin-bottom: 9px; margin-top: 25px;" />
                                    <img src="img/pdf9img2b.png" data-class="fadeIn" id="o10s61gra2" style="display: none;margin-top: 33px;" />
                                  
                                </div>
                                <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                    <img id="o10s62img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none;" />
                                    <div class="text" style="margin-left: 38px;">
                                        <br />
                                        <div data-class="fadeIn" id="o10s62txt1" style="display: none; margin-left: -20px; margin-top: -40px;">
                                            <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 123px;" />
                                            <p style="padding-left: 25px;">
                                                So, four-year survival data from the ongoing pivotal phase 2 study of ADCETRIS in relapsed or refractory sALCL show that the median overall survival is 55.1 months and the estimated 4-year survival is 64%.<sup>2</sup> The estimated 1-year survival was 70%.<sup>1</sup> This survival data support ADCETRIS as a strong treatment option for patients with relapsed/refractory sALCL.

                                            </p>
                                            <br />
                                        </div>
                                        <div data-class="fadeIn" id="o10s62txt2" style="display: none; margin-left: -20px;">
                                            <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                            <p style="padding-left: 25px;">
                                                We will publish and share more data as results become available. The data so far show that ADCETRIS is an option in patients when previously there was none.
                                            </p>
                                            <br />
                                        </div>
                                        <div data-class="fadeIn" id="o10s62txt3" style="display: none; margin-left: -20px;">
                                            <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 123px;" />
                                            <p style="padding-left: 25px;">
                                                In a significant number of patients, complete durable clinical responses are observed with the added benefit of a reduction in disease symptoms.
                                            </p>
                                            <br />
                                        </div>
                                    </div>
                                </div>
                                <div style="width: 45%; float: right; margin-top: -21px; margin-right: -30px;">
                                    <img src="img/O11img1a.png" data-class="fadeIn" id="o10img1" style="width:370px; display: none; margin-bottom: -21px; margin-top: 25px;" />
                                    <img src="img/O11img2a.png" data-class="fadeIn" id="o10img2" style="width:370px; display: none; margin-bottom: -22px; margin-top: 25px;" />
                                    <img src="img/O11img3a.png" data-class="fadeIn" id="o10img3" style="width:370px; display: none; margin-bottom: 9px; margin-top: 25px;" />

                                </div>
                                <div>
                                    <div>
                                        <img src="img/S1BG1.png" data-class="fadeIn" id="slide6img1" style="display: none; position: absolute; width: 75%; margin-left: 99px; margin-top: -27px;" />
                                        <img src="img/S2BG2.png" data-class="fadeIn" id="slide6img2" style="display: none; position: absolute; width: 75%; margin-left: 99px; height: 519px; margin-top: -27px;" />
                                        <div style="color: white; margin-left: 95px; position: relative;">
                                            <p id="s6txt1" style="color: white; padding-top: 130px; padding-left: 62px; width: 748px; display: none;">
                                                Check to establish customer acceptance of this response, and identify any outstanding
                                                aspects of this objection to address.
                                            </p>
                                            <br />
                                            <br />
                                            <p id="s6txt2" style="color: white; padding-left: 62px; width: 748px; display: none;">
                                                Emphasise the benefits of continuing ADCETRIS when following the licensed indication.
                                            </p>
                                        </div>
                                    </div>
                                </div>
                                <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                    <img id="slide7img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: -45px; display: none;" />
                                    <div class="text" style="margin-left: 38px; margin-top: -22px;">
                                        <br />
                                        <p id="s7txt1" style="display: none;">
                                            ADCETRIS is a treatment option for patients who can achieve a long duration of survival.
                                            However, patients must be treated according to the license to give patients the
                                            best possibility of achieving optimal outcomes.
                                        </p>
                                        <br />
                                        <br />
                                        <br />
                                        <p id="s7txt2" style="display: none;">
                                            Moreover, when used for the licensed period, Hodgkin lymphoma patients had a median
                                            OS of 40.5 months and for sALCL patients, median OS has not yet been met at 33.4
                                            months
                                        </p>
                                        <br />
                                    </div>
                                </div>
                                <div style="width: 45%; float: right; margin-right: -30px; margin-top: -10px;">
                                    <img src="img/S6P1.png" data-class="fadeIn" id="slide7img2a" style="width: 180px; display: none; margin-bottom: 4px; margin-top: -47px;" />
                                    <img src="img/pdf9img2.png" data-class="fadeIn" id="slide7img3a" style="width: 180px; display: none; margin-bottom: -22px;" />
                                    <img src="img/S6P1.png" data-class="fadeIn" id="slide7img2" style="width: 180px; display: none; margin-bottom: 9px; margin-top: -35px;" />
                                    <img src="img/file3.png" data-class="fadeIn" id="slide7img3" style="width: 280px; display: none;" />
                                </div>
                            </div>
                            </div>
                        </div>
                <div id="Obj11" style="display: none;">

                    <div id="Obj11ref" style="display: none;" class="Obj11ref">
                        <b>No References</b><br />
                    </div>


                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div class="playBody">
                        </div>
                    </div>

                </div>

                <div id="slide11" style="display: none;" class="slide1ref">
                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div id="slide11ref" style="display: none;" class="slide11ref">
                            <!--<b>No References</b><br />-->
                            <ol>
                                <li>Moskowitz AJ, Hamlin PA, Perales M-A, et al. Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma. <i>J. Clin. Oncol</i>. 2012;31(4):456-460. doi:10.1200/JCO.2012.45.3308.
</li>
                                <li>Ghesquières H, Stamatoullas A, Casasnovas O, et al. Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients. Leuk. <i>Lymphoma</i> 2013;54(11):2399-2404. doi:10.3109/10428194.2013.776165.
</li>
                                <li>Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, et al,. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. <i>J. Clin. Oncol</i>. 2012 Jun 20;30(18):2183-9.
</li>
                                <li>ADCETRIS®. Summary of Product Characteristics. 22 August 2014. Available at European Medicines Agency Web site http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002455/WC500135055.pdf. Accessed on 26 June 2015.
</li>
                                <li>Levact. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Levact/human_referral_000199.jsp&mid=WC0b01ac05805c516f
</li>
                            </ol>
                        </div>
                        <div class="playBody" style="margin-top: 10px; overflow: hidden;">
                            <div data-class="fadeInDown" class="breakout" style="display: none; margin-left: 30px;  text-align: center;"
                                id="s11txt1">
                                <p style="padding-left: 40px; font-size: 20px;">
                                    Objection 11
                                    <br />
                                    “Why should I prescribe ADCETRIS to my pre-SCT patients when I achieve good response rates with the cheaper bendamustine?”



                                </p>
                            </div>
                            <div>
                                <img src="img/S0BG1.png" data-class="fadeIn" id="o11s64img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />
                                <img src="img/o11s64txt1.png" data-class="fadeIn" id="o11s64txt1" style="display: none; width: 236px; float: right; margin-right: 360px; position: relative; margin-top: 10px;" />
                            </div>
                            <div>
                                <img src="img/S1BG1.png" data-class="fadeIn" id="o11s64img2" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />
                                <img src="img/o11s64txt2.png" data-class="fadeIn" id="o11s64txt2" style="display: none; width: 229px; float: right; margin-right: 349px; position: relative; margin-top: 10px;" />
                            </div>
                            <div>
                                <div>
                                    <img src="img/S2BG2.png" data-class="fadeIn" id="o11s65img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px; height: 514px;" />
                                </div>
                                <p id="o11s65txt1" style="margin-left: 140px; padding-top: 78px; color: #FFF; display: none; position: relative;">
                                    Clarify what the main concern of your customer actually is
                                </p>
                                <p id="o11s65txt2" style="margin-left: 140px; padding-top: 50px; color: #FFF; display: none; position: relative;">
                                    You may ask the following questions :
                                </p>
                                <ul style="margin-left: 60px; padding-top: 20px; width: 580px;">
                                    <div data-class="fadeIn" id="o11s65txt3" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">Regarding efficacy, what are your treatment goals for your pre-SCT Hodgkin lymphoma patients? For example, do you aim to achieve the best possible response or the longest duration of response, or will your patients eventually receive allogeneic SCT? With this in mind, what is your main concern with prescribing ADCETRIS?
                                        </li>
                                        <br />
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o11s65txt4" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">Regarding costs, you note that bendamustine is less expensive than ADCETRIS. What specific concerns do you have about costs?   

                                        </li>
                                        <br />
                                        <br />
                                    </div>

                                </ul>
                            </div>

                            <div>
                                <img src="img/S1BG1.png" data-class="fadeIn" id="o11s69img1" style="display: none; position: absolute; width: 75%; margin-top: -27px; margin-left: 80px;" />
                                <img src="img/o11s69txt1.png" data-class="fadeIn" id="o11s69txt1" style="display: none; width: 243px; float: right; margin-right: 328px; position: relative; margin-top: -25px;" />
                                <img src="img/o11s69txt2.png" data-class="fadeIn" id="o11s69txt2" style="display: none; width: 216px; float: right; margin-right: 347px; position: relative; margin-top: -25px;" />
                                <img src="img/o11s69txt3.png" data-class="fadeIn" id="o11s69txt3" style="display: none; width: 243px; float: right; margin-right: 330px; position: relative; margin-top: -25px;" />
                            </div>

                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="o11s66img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none; height: 200px;" />
                                <div class="text" style="margin-left: 25px;">
                                    <div data-class="fadeIn" id="o11s66txt1" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            Regarding efficacy, limited data are available on the use of bendamustine in patients with Hodgkin lymphoma.
                                        </p>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o11s66txt2" style="display: none; margin-top: -20px; width: 386px; margin-left: -10px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            <b>Only one Phase II study with bendamustine has been performed to date.</b> It included just 36 relapsed/refractory Hodgkin lymphoma patients, 81% of whom received prior allogeneic and/or autologous SCT.
                                        </p>
                                    </div>
                                    <div data-class="fadeIn" id="o11s66txt3" style="display: none; margin-top: -13px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            The <b>ORR</b> in the study was <b>53%,</b> while <b>CR</b> was achieved in <b>33%</b> of patients corresponding to a small absolute number of 12<sup>1</sup>
                                        </p>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o11s66txt4" style="display: none; margin-top: -17px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            <b>Median response duration</b> in patients with <b>OR</b> was only <b>5 months</b><sup>1</sup>
                                        </p>
                                    </div>
                                    <div data-class="fadeIn" id="o11s66txt5" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            <b>20%</b> of patients experienced <b>grade ≥3 thrombocytopenia</b> and <b>14% grade ≥3 anaemia</b><sup>1</sup>
                                        </p>
                                    </div>
                                    <div data-class="fadeIn" id="o11s66txt6" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            Similar results, were reported in the French compassionate-use programme.<sup>2</sup>
                                        </p>
                                    </div>



                                </div>
                                <div>
                                    <img src="img/slide-66.png" data-class="fadeIn" id="o11s66gra1" style="display: none; margin-left: 199px; margin-top: 44px;" />
                                </div>
                            </div>

                            <div style="width: 45%; float: right; margin-top: -21px; margin-right: -30px;">

                                <img src="img/S6P1.png" data-class="fadeIn" id="o11s66rep1" style="width: 180px; margin-bottom: 9px; margin-top: 34px; display: none;" />

                                <img src="img/S4P1.png" data-class="fadeIn" id="o11s66rep2" style="width: 180px; display: none; margin-bottom: 9px; margin-top: 25px;" />
                                <img src="img/S4P1.png" data-class="fadeIn" id="o11s66rep4" style="width: 180px; display: none; margin-bottom: 9px; margin-top: 25px;" />


                                <img src="img/S5P1.png" data-class="fadeIn" id="o11s66rep3" style="width: 180px; display: none; margin-bottom: 30px; margin-top: 25px;" />

                                <img src="img/o11s68box1.png" data-class="fadeIn" id="o11s68box1" style="width: 340px; margin-left: -35px; display: none;" />
                                <img src="img/Conbox.png" data-class="fadeIn" id="o11s68txt3" style="width: 340px; margin-left: -35px; margin-top: 20px; display: none;" />
                                <img src="img/o11s68box2.png" data-class="fadeIn" id="o11s68box2" style="width: 340px; margin-left: -35px; display: none;" />
                                <img src="img/o11s68box3.png" data-class="fadeIn" id="o11s68box3" style="width: 340px; margin-left: -35px; display: none; margin-top: 34px;" />
                            </div>

                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="o11s67bg1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none; height: 200px;" />
                                <div class="text" style="margin-left: 25px;">
                                    <div data-class="fadeIn" id="o11s67txt1" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            In comparison, <b>data for ADCETRIS</b> in this population are based on a <b>larger Phase II</b> study in 102 patients, all of whom underwent prior autologous SCT.<sup>3</sup>
                                        </p>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o11s67txt2" style="display: none; margin-top: -20px; width: 386px; margin-left: -10px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            Patients achieved a <b>higher ORR of 75%</b>, with a comparable <b>CR rate of 34%<sup>3</sup></b>
                                        </p>
                                    </div>
                                    <div data-class="fadeIn" id="o11s67txt3" style="display: none; margin-top: -13px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px;" />
                                        <p style="padding-left: 30px; text-align: left;">
                                            <b>Median response duration</b> was <b>longer: 6.7 months</b> in ORR patients<sup>3</sup>
                                        </p>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o11s67txt4" style="display: none; margin-left: -20px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 21px;" />
                                        <p style="padding-left: 25px;">
                                            <b>Only 8%</b> of patients experienced <b>grade ≥3 thrombocytopenia</b> and <b>6% grade ≥3 anaemia</b><sup>3</sup>
                                        </p>
                                    </div>
                                </div>

                                <div>
                                    <img src="img/slide-67.png" data-class="fadeIn" id="o11s67gra2" style="display: none; margin-left: 203px; margin-top: 17px;" />
                                </div>
                            </div>


                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="o11s68bg1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none;" />
                                <div class="text" style="margin-left: 38px;">

                                    <div data-class="fadeIn" id="o11s68txt1" style="display: none; margin-left: -20px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 21px;" />
                                        <p style="padding-left: 25px;">
                                            Regarding costs, there are currently no cost-effectiveness analyses comparing the use of bendamustine and ADCETRIS.
                                        </p>
                                    </div>
                                    <div data-class="fadeIn" id="o11s68txt2" style="display: none; margin-left: -20px; margin-top: 35px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 21px;" />
                                        <p style="padding-left: 25px;">
                                            Adverse events caused by bendamustine have associated costs and the cost of concomitant G-CSF use must be considered. For example in the French compassionate use programme, 18% of patients received G-CSF, 11% blood transfusions, and 7% platelet transfusions.<sup>2</sup>
                                        </p>
                                    </div>




                                    <div data-class="fadeIn" id="o11s68txt4" style="display: none; margin-left: -20px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 21px;" />
                                        <p style="padding-left: 25px;">
                                            Importantly, only ADCETRIS is currently approved by the European Medicines Agency (EMA) for the treatment of patients with relapsed/refractory Hodgkin lymphoma.<sup>4</sup> 
                                        </p>
                                    </div>
                                    <div data-class="fadeIn" id="o11s68txt5" style="display: none; margin-left: -20px; margin-top: 35px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 21px;" />
                                        <p style="padding-left: 25px;">
                                            In contrast, bendamustine is EMA-approved for use in patients with rituximab-refractory NHL, fludarabine ineligible CLL, and elderly SCT-ineligible MM, but not Hodgkin lymphoma.<sup>5</sup>

                                        </p>
                                    </div>

                                    <div data-class="fadeIn" id="o11s68txt5a" style="display: none; margin-left: -20px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 21px;" />
                                        <p style="padding-left: 25px;">
                                            Both bendamustine and ADCETRIS appear to achieve good CRs in patients with relapsed/refractory Hodgkin lymphoma; however, studies with ADCETRIS consistently report higher ORRs in a much larger patient population.<sup>1-4</sup>
                                        </p>
                                    </div>

                                    <div data-class="fadeIn" id="o11s68txt5b" style="display: none; margin-left: -20px; margin-top: 35px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 21px;" />
                                        <p style="padding-left: 25px;">
                                            In addition, safety data indicate that ADCETRIS may be more tolerable in patients with Hodgkin lymphoma.
                                        </p>
                                    </div>
                                    <div data-class="fadeIn" id="o11s68txt5c" style="display: none; margin-left: -20px; margin-top: 35px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 21px;" />
                                        <p style="padding-left: 25px;">
                                            Although bendamustine itself may be less expensive than ADCETRIS, there are additional factors to consider such as duration of treatment, cost of managing adverse events, and availability of reimbursement.
                                        </p>
                                    </div>

                                </div>

                            </div>





                        </div>
                    </div>
                </div>
                <div id="Obj12" style="display: none;">
                    <div id="Obj12ref" style="display: none;" class="Obj12ref">
                        <b>No References</b><br />
                    </div>



                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div class="playBody">
                        </div>
                    </div>

                </div>

                <div id="slide12" style="display: none;" class="slide12ref">
                    <div style="height: 550px; width: 100%; float: left; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div id="slide12ref" style="display: none;" class="slide12ref">
                            <!--<b>No References</b><br />-->
                            <ol>
                                <li>Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study. <i>J. Clin. Oncol</i>. 2000;18(13):2615-9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10893294. Accessed July 1, 2015.
</li>
                                <li>Venkatesh H, Di Bella N, Flynn TP, Vellek MJ, Boehm KA, Asmar L. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin’s lymphoma. <i>Clin. Lymphoma</i> 2004;5(2):110-5.
</li>
                                <li>Validire P, Fermé C, Brice P, et al. A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin’s lymphoma patients. <i>Anticancer. Drugs</i> 2008;19(3):309-15.
</li>
                                <li>Oki Y, Pro B, Fayad LE, et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.<i>Cancer</i> 2008;112(4):831-6. doi:10.1002/cncr.23237.
</li>
                                <li>Mendler JH, Kelly J, Voci S, et al. Bortezomib and gemcitabine in relapsed or refractory Hodgkin’s lymphoma. <i>Ann. Oncol</i>. 2008;19(10):1759-1764. doi:10.1093/annonc/mdn365.
</li>
                                <li>Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. <i>J. Clin. Oncol</i>. 2012;30(18):2183-9. doi:10.1200/JCO.2011.38.0410.
</li>
                                <li>Rothe A, et al. Blood (ASH Annual Meeting Abstracts). 2012; 120:abstract 2743.
</li>
                                <li>Bartlett N, Niedzwiecki D, Johnson J, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. <i>Ann. Oncol</i>. 2007;18(6):1071-1079. doi:10.1093/annonc/mdm090.
</li>
                                <li>Böll B, Bredenfeld H, Görgen H, et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. <i>Blood</i> 2011;118(24):6292-8. doi:10.1182/blood-2011-07-368167.
</li>
                                <li>Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. <i>Haematologica</i> 2007;92(1):35-41.
</li>
                                <li>Baetz T, Belch A, Couban S, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.<i> Ann. Oncol</i>. 2003;14(12):1762-7.
</li>
                                <li>ADCETRIS®. Summary of Product Characteristics. 22 August 2014. Available at European Medicines Agency Web site http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002455/WC500135055.pdf. Accessed on 26 June 2015.
</li>
                                <li>Eli Lilly and Company Limited. Gemcitabine SmPC 2013.
</li>
                            </ol>
                        </div>
                        <div class="playBody" style="margin-top: 10px; overflow: hidden;">
                            <div data-class="fadeInDown" class="breakout" style="display: none; margin-left: 30px;  text-align: center;"
                                id="s12txt1">
                                <p style="padding-left: 40px; font-size: 20px;">
                                    Objection 12
                                    <br />
                                    “I have good experiences prescribing gemcitabine-based regimens to relapsed/refractory Hodgkin lymphoma and sALCL patients; therefore, I see no reason why I should try ADCETRIS?”



                                </p>
                            </div>
                            <div>
                                <img src="img/S0BG1.png" data-class="fadeIn" id="o12slide0img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />
                                <img src="img/O12doc.png" data-class="fadeIn" id="o12slide0img2" style="display: none; width: 243px; float: right; margin-right: 355px; position: relative; margin-top: 10px;" />
                            </div>
                            <div>
                                <img src="img/S1BG1.png" data-class="fadeIn" id="o12slide1img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px;" />
                                <img src="img/O12txt1.png" data-class="fadeIn" id="o12slide1img2" style="display: none; width: 233px; float: right; margin-right: 344px; position: relative; margin-top: 10px;" />
                            </div>
                            <div>
                                <div>
                                    <img src="img/S2BG2.png" data-class="fadeIn" id="o12slide2img1" style="display: none; position: absolute; width: 75%; margin-top: 8px; margin-left: 80px; height: 514px;" />
                                </div>

                                <p id="o12txt0" style="margin-left: 140px; padding-top: 78px; color: #FFF; display: none; position: relative; width: 676px;">
                                    It is important to clarify how your customer defines “good experiences”  and also to clarify which gemcitabine-based regimens he/she is using.

                                </p>
                                <p id="o12txt1" style="margin-left: 140px; padding-top: 34px; color: #FFF; display: none; position: relative;">
                                    You may ask the following questions :

                                </p>
                                <ul style="margin-left: 60px; padding-top: 20px; width: 745px;">
                                    <div data-class="fadeIn" id="o12txt2" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">You indicated that you have good experiences with gemcitabine-based regimens. What do you mean by “good experiences”? Are you looking at response rates, duration of response, survival, stem cell mobilisation, tolerability, other?</li>

                                    </div>
                                    <div data-class="fadeIn" id="o12txt3" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">Not all gemcitabine-based regimens achieve the same results. Which gemcitabine-based regimens are you using?</li>

                                    </div>
                                    <div data-class="fadeIn" id="o12txt4" style="color: white; margin-left: 95px; margin-top: 20px; display: none; position: relative;">
                                        <li style="color: white;">With this in mind, what is your main concern with prescribing ADCETRIS?</li>
                                    </div>
                                </ul>
                            </div>

                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="o12slide4img1a" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: 1px; display: none;" />
                                <div class="text" style="margin-left: 38px;">
                                    <br />
                                    <div data-class="fadeIn" id="o12s1txt1" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 145px;" />
                                        <p>
                                            Comparison of data from separate trials with ADCETRIS and gemcitabine reveal that treatment with ADCETRIS is associated with better outcomes compared to gemcitabine in the treatment of relapsed/refractory Hodgkin lymphoma and sALCL patients.

                                        </p>
                                    </div>
                                    <div data-class="fadeIn" id="o12s1txt2" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 183px;" />
                                        <p>
                                           Let’s look at the response rates observed in separate trials with ADCETRIS and gemcitabine first.
                                        </p>
                                    </div>
                                </div>
                            </div>
                            <div style="width: 45%; float: right; margin-top: -21px; margin-right: -30px;">
                                <img src="img/S6P1.png" data-class="fadeIn" id="o12s1box1" style="width: 180px; display: none; margin-bottom: -21px; margin-top: 25px;" />

                                <img src="img/S4P1.png" data-class="fadeIn" id="o12s1box2" style="width: 180px; display: none; margin-bottom: 9px; margin-top: 25px;" />

                            </div>


                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="o12slide4img1" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: -18px; display: none;" />
                                <div class="text" style="margin-left: 38px; margin-top: -6px;">
                                    <div data-class="fadeIn" id="o12s4txt1" style="display: none; width: 370px;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 65px;" />
                                        <p>
                                            Studies evaluating gemcitabine as a single agent or in combination with one additional agent reported ORR in the range 20–48%, with CR in the range 0–15%.<sup>1-5</sup>
                                        </p>
                                        <br />
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o12s4txt2" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 84px;" />
                                        <p>
                                            In contrast, in a separate trial evaluating ADCETRIS as a single agent, ORR of up to 75% and CR of up to 33% in relapsed or refractory HL was reported.<sup>6,7</sup>
</p>
                                    </div>



                                </div>
                            </div>
                            <div style="width: 43%; float: right; margin-top: -130px; margin-right: -35px;">
                                <img src="img/S6P1.png" data-class="fadeIn" id="o12box1" style="width: 180px; display: none; margin-bottom: 30px; margin-top: 120px;" />
                                <img src="img/S4P1.png" data-class="fadeIn" id="o12box2" style="width: 180px; margin-bottom: 33px; margin-top: 114px; display: none;" />
                                <img src="img/O12box1a.png" data-class="fadeIn" id="o12box3" style="width: 340px; margin-top: -9px; margin-bottom: 24px; display: none;    margin-left: -18px;" />

                                <img src="img/O12box2a.png" data-class="fadeIn" id="o12box4" style="width: 340px; display: none;    margin-left: -12px;" />




                            </div>



                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="o12slide4img1b" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: -18px; display: none;" />
                                <div class="text" style="margin-left: 38px; margin-top: -6px;">
                                    <div data-class="fadeIn" id="o12s4txt1b" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 96px;" />
                                        <p>
                                            Only gemcitabine-containing regimens with three or more agents have reported response rates (ORR: 70–81%; CR: 17–78%)<sup>8-11</sup> comparable to those of single-agent ADCETRIS.
                                        </p>
                                        <br />
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o12s4txt2b" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 84px;" />
                                        <p>
                                            Available data indicate that patients treated with either ADCETRIS or gemcitabine-based regimens are able to collect sufficient stem cells and proceed to transplantation, if warranted.<sup>6-10</sup>
                                        </p>
                                    </div>



                                </div>
                            </div>
                            <div style="width: 43%; float: right; margin-top: -130px; margin-right: -35px;">
                                <img src="img/S6P1.png" data-class="fadeIn" id="o12box1b" style="width: 180px; display: none; margin-bottom: 30px; margin-top: 120px;" />
                                <img src="img/S4P1.png" data-class="fadeIn" id="o12box2b" style="width: 180px; margin-bottom: 33px; margin-top: 114px; display: none;" />
                                <img src="img/O12box3a.png" data-class="fadeIn" id="o12box3b" style="width: 340px; margin-top: 18px; display: none;    margin-left: -18px;" />
                            </div>
                            <div>
                                <img src="img/S1BG1.png" data-class="fadeIn" id="o12slide1img1a" style="display: none; position: absolute; width: 75%; margin-top: -23px; margin-left: 80px;" />
                                <img src="img/O12txt2.png" data-class="fadeIn" id="o12slide1img2a" style="display: none; width: 243px; float: right; margin-right: 340px; position: relative; margin-top: -19px;" />
                            </div>

                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="o12sa" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: -18px; display: none;" />
                                <div class="text" style="margin-left: 38px; margin-top: -28px;">
                                    <div data-class="fadeIn" id="o12txt1a" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 40px;" />
                                        <p>
                                           <In post-hoc analyses, Safety data from different studies indicate that ADCETRIS may be more tolerable in patients with relapsed/refractory Hodgkin lymphoma <b>than gemcitabine-based regimens containing three or more agents.
                                        </p>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o12txt2a" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 84px;" />
                                        <p>Grade 3/4 haematological adverse events were more common with most gemcitabine-based regimens than with ADCETRIS (e.g. neutropenia, thrombocytopenia, anemia).</p>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o12txt3a" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 99px;" />
                                        <p>The most common non-haematological adverse events were also more common with gemcitabine-based regimens<sup>8-11</sup> than with ADCETRIS<sup>6</sup> (e.g. fatigue, nausea, vomiting).</p>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o12txt4a" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 84px;" />
                                        <p>Importantly, only ADCETRIS is EMA-approved for the treatment of patients with relapsed/refractory Hodgkin lymphoma.<sup>12</sup></p>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o12txt5a" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 115px;" />
                                        <p>In contrast, gemcitabine (GEMZAR®) is EMA-approved in patients with bladder cancer, pancreatic cancer, non-small-cell lung carcinoma (NSCLC), ovarian cancer, and breast cancer, but not Hodgkin lymphoma.<sup>13</sup></p>
                                        <br />
                                    </div>



                                </div>
                            </div>
                            <div style="width: 43%; float: right; margin-top: -130px; margin-right: -35px;">
                                <img src="img/S6P1.png" data-class="fadeIn" id="o12box6a" style="width: 180px; display: none; margin-bottom: 30px; margin-top: 120px;" />
                                <img src="img/S4P1.png" data-class="fadeIn" id="o12box7a" style="width: 180px; margin-bottom: 33px; margin-top: 114px; display: none;" />
                                <img src="img/O12box4a.png" data-class="fadeIn" id="o12box8a" style="width: 340px; margin-top: -9px; margin-bottom: 24px; display: none;" />

                                <img src="img/O12box5a.png" data-class="fadeIn" id="o12box9a" style="width: 340px; display: none;" />




                            </div>


                            <div class="image" style="width: 44%; float: left; margin-right: 100px;">
                                <img id="o12sb" alt="" src="img/S4BG1.png" style="width: 100%; margin-left: 62px; margin-top: -18px; display: none;" />
                                <div class="text" style="margin-left: 38px; margin-top: -4px;">
                                    <div data-class="fadeIn" id="o12txt1b" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 180px;" />
                                        <p>
                                            Based on data from studies assessing gemcitabine regimens and separate studies assessing ADCETRIS, only gemcitabine-containing regimens with three or more agents have reported response rates comparable to those of single-agent ADCETRIS in patients with relapsed/refractory Hodgkin<br/> lymphoma.<sup>8-11</sup>
                                        </p>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o12txt2b" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 101px;" />
                                        <p>Although the gemcitabine regimens are better tolerated than comparable chemotherapy regimens, available data suggest that patients will tolerate single-agent ADCETRIS better than any of these 3- or 4-drug combinations.<sup>6,8-11</sup></p>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o12txt3b" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 150px;" />
                                        <p>With the exception of PVAG study in elderly patients with relapsed/refractory Hodgkin lymphoma, available data indicate that single-agent ADCETRIS achieves comparable or better response rates, including CR, and has a better tolerability profile than multi-agent gemcitabine-based regimens.<sup>6,8-11</sup></p>
                                        <br />
                                    </div>
                                    <div data-class="fadeIn" id="o12txt4b" style="display: none;">
                                        <img src="../common/img/bullet01.png" style="width: 12px; height: 12px; float: left; margin: 7px; margin-bottom: 84px;" />
                                        <p>Therefore, in most relapsed/refractory Hodgkin lymphoma patients, ADCETRIS may be the best choice.</p>
                                        <br />
                                    </div>




                                </div>
                            </div>
                            <div style="width: 43%; float: right; margin-top: -130px; margin-right: -35px;">
                                <img src="img/S6P1.png" data-class="fadeIn" id="o12box6b" style="width: 180px; display: none; margin-bottom: 30px; margin-top: 120px;" />
                                <img src="img/S4P1.png" data-class="fadeIn" id="o12box7b" style="width: 180px; margin-bottom: 33px; margin-top: 114px; display: none;" />
                            </div>

                        </div>












                    </div>
                </div>


                <div id="slide13" style="display: none;">
                    <!-- <div class="topic-bar">
                        <div id="topic-title">Title</div>
                    </div>-->
                    <!--Body -->
                    <div style="height: 550px; width: 100%; margin: 0px auto; border: 2px solid rgba(127, 145, 145, 0.12); border-radius: 10px; background-color: rgba(255, 255, 255, 0.2);">
                        <div class="playBody">
                            <div data-class="fadeInDown" class="breakout" style="display: none; text-align: center; /*height: 95px; */"
                                id="s24img1">
                                <p class="" style="font-size: 20px; position: relative; text-align: center;">
                                    End of Module!
                                </p>
                                <p class="fadeInDown" id="s24img2" style="display: none; text-align: left">
                                    Please close the window and attempt the post-test in order to complete the course.
                                </p>
                            </div>
                        </div>
                    </div>
                </div>
               
            </div>
          
            <div id="slideLabel" style="margin: 0px auto;
	width: 1024px;  font-size: 10pt;
	padding-left: 40px; display: none;">For internal training purposes only - not to be used or shared outside Takeda</div>
        </div>
      
    </div>
    <div id="footer" style="width: 1024px; margin: 0 auto;">
        <div class="container" style="">
            <table style="width: 100%">
                <tr>
                    <td>
                        <img src="../common/img/takeda.png" style="float: left; width: 105px; margin-top: 3px; margin-right: 10px; margin-left: -25px;" />
                    </td>
                    <td>
                        <img onmouseover="HideToolTip(this)" data-toggle="tooltip" title="Play / Pause" class="effect"
                            id="toggelbutton"  class="effect" src="../common/img/playBtn.png" style="float: left; margin-top: -10px;"
                            onclick="play()" />
                    </td>
                    <td>
                        <div style="float: left;">
                            <input id="progress-bar" type="text" data-slider="true" data-slider-highlight="true">
                            <div class="slider-control">
                                <span id="slideCount">Slide 0 of 00</span> <span style="float: right;"><span id="timeduration">0:00</span> / <span id="slideduration">0:00</span></span>
                            </div>
                        </div>
                    </td>
                    <td>
                        <img onmouseover="HideToolTip(this)" data-toggle="tooltip" data-placement="left"
                            title="Previous Slide " class="effect" src="../common/img/prevBtn.png" style="margin-top: -10px;"
                            onclick="Prev()" />
                    </td>
                    <td>
                        <img onmouseover="HideToolTip(this)" data-toggle="tooltip" title="Next Slide" class="effect" id="NxtImg"
                            src="../common/img/nxtBtn.png" style="margin-top: -10px;" onclick="Next()" />
                    </td>
                    <td>
                        <img onclick="ShowHelp();" id="showHelp" src="../common/img/smallicon2.png" style="margin-top: -10px; margin-left: 35px;" />
                    </td>
                    <td>
                        <a href="pdf/Transcript_Module_08_ver_1.00.pdf" target="_blank">
                            <img onmouseover="HideToolTip(this)" data-toggle="tooltip" title="Print" class="effect"
                                src="../common/img/smallicon3.png" style="margin-top: -10px;" /></a>
                    </td>
                </tr>
            </table>
            <!--  <img class="effect" src="img/pauseBtn.png" style="float: left; margin-top: -10px;" onclick="pause()" />-->
        </div>
    </div>
    <div class="modal fade" id="AnswerModal" data-backdrop="static" tabindex="-1" role="dialog"
        aria-labelledby="myModalLabel" aria-hidden="true">
        <div class="modal-dialog">
            <div class="modal-content">
                <div class="modal-body">
                </div>
                <div class="modal-footer">
                    <button type="button" onclick="onclickAnswerContinue()" class="btn btn-primary">
                        Continue</button>
                </div>
            </div>
        </div>
    </div>

    <script>
        $('img').tooltip({ trigger: "focus" });

    </script>
</body>
</html>
